The Journal of the American Diabetes Association

diabetes

...e 19 • 1970

INDEX

By Subject and Author

RECEIVED
APR 27 1971
THE LIBRARY
... STATE UNIVERSITY



Copyright 1971, by American Diabetes Association, Inc.

DIABETES®

The Journal of the American Diabetes Association

EDITOR, HARVEY C. KNOWLES, JR., M.D., *Cincinnati*

ASSOCIATE EDITORS: DAVID M. KIPNIS, M.D., *St. Louis* • HENRY T. RICKETTS, M.D., *Chicago*

ADVISORY EDITORS: CHARLES H. BEST, M.D., *Toronto* • FRANK N. ALLAN, M.D., *Boston*

ABSTRACTS EDITOR, JOHN A. GALLOWAY, M.D., *Indianapolis* • MANAGING EDITOR, EDWARD W. SANDERSON, *New York*

EDITORIAL BOARD

TERM EXPIRING DECEMBER 1970

JOHN W. ENSINCK, M.D., *Seattle*
STEFAN S. FAJANS, M.D., *Ann Arbor*
PETER H. FORSHAM, M.D., *San Francisco*
GEROLD M. GRODSKY, PH.D., *San Francisco*
PHILIP M. LECOMPTE, M.D., *Boston*
IRVING H. LEOPOLD, M.D., *New York*
ROGER H. UNGER, M.D., *Dallas*
PETER H. WRIGHT, M.D., *Indianapolis*

TERM EXPIRING DECEMBER 1971

JAMES ASHMORE, PH.D., *Indianapolis*
RUBIN BRESSLER, M.D., *Durham*
FREDERICK C. GOETZ, M.D., *Minneapolis*
CHRISTIAN R. KLIMT, M.D., DR. P.H., *Baltimore*
ARNOLD LAZAROW, M.D., PH.D., *Minneapolis*
RACHMIEL LEVINE, M.D., *New York*
ALEXANDER MARBLE, M.D., *Boston*
THEODORE B. VAN ITALLIE, M.D., *New York*

TERM EXPIRING DECEMBER 1972

GEORGE F. CAHILL, JR., M.D., *Boston*
MARVIN CORNBLATH, M.D., *Baltimore*
T. S. DANOWSKI, M.D., *Pittsburgh*
PAUL E. LACY, M.D., *St. Louis*
HIROMICHI T. NARAHARA, M.D., *Albany*
DANIEL PORTE, JR., M.D., *Seattle*
GERALD A. WRENSHALL, PH.D., *Toronto*

ABSTRACTORS

TERM EXPIRING DECEMBER 1970

JOSEPH D. BROWN, M.D., *Iowa City*
PAUL S. ENTMACHER, M.D., *New York*
JEROME M. FELDMAN, M.D., *Durham*
BERT F. KELTZ, M.D., *Oklahoma City*
CHARLES R. SHUMAN, M.D., *Philadelphia*

TERM EXPIRING DECEMBER 1971

BURIS R. BOSHELL, M.D., *Birmingham, Ala.*
WAYNE V. GREENBERG, M.D., *Pittsburgh*
RONALD K. KALKHOFF, M.D., *Milwaukee*
CHARLES A. ROSENBERG, M.D., *Washington, D.C.*
THOMAS G. SKILLMAN, M.D., *Columbus, Ohio*
LEON S. SMELO, M.D., *Birmingham, Ala.*

TERM EXPIRING DECEMBER 1972

MARIOS C. BALODIMOS, M.D., *Boston*
PAUL BECK, M.D., *Denver*
DAVID R. CHALLONER, M.D., *Indianapolis*
PHILIP FELIG, M.D., *New Haven*
THOMAS J. MERIMEE, M.D., *Boston*
JAMES E. VANCE, M.D., *Indianapolis*

DIABETES is published by the American Diabetes Association, Inc., to provide an official Journal for the Association and to furnish the medical profession with information concerning diabetes and related fields of medicine.

Contributions are invited from practicing physicians, clinical and laboratory investigators, and others who have data of importance to offer in these fields. Manuscripts, if suitable, will be accepted providing that the text has not been printed elsewhere.

Matter appearing in DIABETES is copyrighted. Permission to reproduce all or part of papers appearing in it may be granted on application, under appropriate conditions and if proper credit is given. Such permission should be requested by written application to the Secretary of the Association.

All signed articles and editorials are the responsibility of the author(s) and not that of the American Diabetes Association. The Editors will be pleased to consider for publication papers presented at the Annual Meeting of the American Diabetes Association.

Manuscript Specifications: The length of manuscripts (not including special articles or letters) should be limited to 5,000 words, exclusive of illustrations, etc. Exceptions to this limitation will be made at the discretion of the Editors.

Communications for the "Brief Notes and Comments" department should not exceed 1,000 words except in unusual circumstances. Figures and tables in these brief communications should be limited to one of each, and references should not exceed twenty in number.

Manuscripts should be typewritten, with double spacing and, if possible, submitted in triplicate together with three copies of figures and photomicrographs.

References should be presented in the style of the following examples: For Periodicals—Banting, F. G., and Best, C. H.: The internal secretion of the pancreas. J. Lab. Clin. Med. 7:251-66, Feb. 1922. For Books—Allen, Frederick M.: Studies Concerning Glycosuria and Diabetes. Cambridge, Harvard University Press, 1913, p. 461.

An abstract or summary of the content of the paper in not more than 250 words should usually appear at the beginning. This should be self-contained and understandable without reference to the text.

Photographs, drawings, and figures should be suitable for reproduction purposes. Photographs should be unmounted, untrimmed glossy prints. The names of authors should appear on the back. The tops of photographs and figures should be indicated.

Galley proofs are sent to the principal author of each paper, with a price list and order blank for reprints.

All manuscripts and editorial correspondence should be addressed to the Editorial Office, DIABETES, American Diabetes Association, Inc., 18 East 48th Street, New York, New York 10017.

Subscription and Advertising Information

DIABETES: *The Journal of the American Diabetes Association* is published every month by the Association at 18 East 48th Street, New York, New York 10017.

© American Diabetes Association, Inc., 1971. All rights reserved under International and Pan-American Copyright Convention.

Members receive the Journal as part of their membership privileges. The annual subscription rates for nonmembers are as follows: United States, U. S. possessions, Canada and the Postal Union of the Americas and Spain, $20.00 for one year; $35.00 for two years; $50.00 for three years. Individual copies $2.00. For overseas subscriptions, add $2.00 per year for postage.

Medical students and physicians within five years after completion of medical school and bioscientists who are predoctoral or not more than two years postdoctoral: 50 per cent of the rates quoted in the previous paragraph, plus overseas postage where applicable.

Correspondence concerning subscriptions should be addressed to the Subscription Department, DIABETES. Checks, money orders and drafts for subscriptions should be made payable to the American Diabetes Association, Inc., and sent to the aforementioned address.

All inquiries about advertising and other business matters should be addressed to the Executive Director of the American Diabetes Association. The publishers reserve in their full discretion the right to accept or reject any proposed advertising and the right to cancel any advertising contract.

SUBJECT INDEX 1970

This index covers all reading matter in Volume 19 of DIABETES. Entries marked with an asterisk (*) indicate material that appeared in the Abstracts only. The Author Index appears on page 30.

A

ACETOHEXAMIDE
and potassium, *134

ACETYL COENZYME A CARBOXYLASE
inhibition, *736

ACID ESTERASE
and Wolman's disease, *886

ACID MUCOPOLYSACCHARIDES
of diabetic kidney, 161-169
and scleredema, *884

ACIDOSIS, DIABETIC
and fructose, *344
and gangrene, 882-883
and gluconeogenesis, *135, *735
and lipemia retinalis and hyperchylomicronemia
and insulin, *670
and liver function, *888

ACIDOSIS, LACTIC
and diabetes, *670
and nonketotic coma, *344

ACIDOSIS, METABOLIC
aketotic hyperosmolar
in heat stroke, *531

ACIDS
acetylsalicylic
and glucose absorption, *205
amino. *See* Amino acids.
citric
cycle in diabetic rat liver, *202
dialuric, 84
ethacrynic
and diabetes insipidus, *528
and potassium ion transport and glycolysis, *671
ethanol extracts
in new insulin isolation technic, 831-836
guanidinoacetic
and insulin secretion, *734-735
hyaluronic and chondroitin sulfuric
in skin of alloxan diabetic rats, 732-733
hydrochloric
and insulin release, *950, *952
iodoacetic
and lipolysis, *670
lactic
and adipose tissue lipolysis, *133
and fructose infusion, *344
nicotinic
and adenylcyclase activity in fat cells, *673
orotic, *592
sialic, *471
stearic
and insulin, *595-596
2-thiophenecarboxylic, *596
γ-aminobutyric
and focal seizures, *594

ACROMEGALY
and hypophyseal hyperactivity, *534
and insulin secretion, *951
and serum insulin, *283-284

ACTH. *See* Adrenocorticotrophic hormone.

ACTINOMYCIN D
and free fatty acids, *953

ADDISON'S DISEASE
and diabetes, *134
and Candida meningitis, 438-441, 443-444

ADENOSINE 3′, 5′ CYCLIC MONOPHOSPHATE
and blocking agents, 455-456
and glucagon action, 427-428
and insulin release, *201, 480-485, 837, 839-840
urinary excretion study, *530

ADENOSINE TRIPHOSPHATE
and phenformin action, 50-52

ADENYLCYCLASE
and alloxan, *593
in fat cell particles, *673
and insulin secretion, *201

ADRENAL GLANDS
and alloxan diabetes, 313-314, 321
and diazoxide analog therapy, 635
insufficiency
and Candida meningitis in juvenile diabetic, 438-441, 443-444
and pernicious anemia, 722

ADRENALECTOMY
and diazoxide analog therapy, 633
and glycogen synthesis, *137, 920-921
and insulin secretion in fasted mice, *885

ADRENERGIC BLOCKING AGENTS
alpha
and growth hormone, insulin, free fatty acids and glucose, *738
and insulin secretion, *201, 668-692, *738, *949
and pheochromocytoma, *598
beta, 455-456
and alpha adrenergic blocking agents, *738
and cardiac decompensation, *738
and diazoxide, 228-232
and insulin release, *201, 480, 484-485
and juvenile diabetes, *201
and serum glucose, insulin, free fatty acids, and acetone bodies, *670
and catecholamine release after diazoxide, 637
and insulin secretion, 455-456
and serotonin inhibition of insulin release, 481-482

ADRENERGIC RECEPTORS
beta
and plasma amino acid response to insulin, *348
and insulin secretion, *201

DIABETES: VOLUME 19 (1970) PAGE NUMBERS BY ISSUE

January, 1-80
February, 81-144
March, 145-208
April, 209-288
May, 289-352
Supplement 1, 353-408
June, 409-474
July, 475-538
August, 539-602
September, 603-682
October, 683-746
Supplement 2, 747-830
November, 831-894
December, 895-958

ADRENERGIC STIMULATING AGENTS
beta
and insulin release following glibenclamide therapy, *137-138

ADRENOCORTICOTROPHIC HORMONE
and adenylcyclase activity in fat cells, *673
and insulin release, 427, 484-485
and lipolysis, *205

AGE
and blood glucose tests, *135
and diabetes incidence in Israel, 940-941
of diabetes onset
and hereditary studies, *530
and diabetic neuropathy, *73
and glucose tolerance, 186-188, *206
in normal subjects, 844, 845
and hyperzincuria, 244
of infants and children in capillary blood sugar study, 177
and mucopolysaccharide changes in diabetic kidneys, 163
of patients in UGDP study, 750, 758, 777, 798, 809
and blood pressure, 763, 767
and body weight, 763, 765
and cardiothoracic ratios, 769
and cardiovascular risk factors, 770, 771
and fasting blood glucose values, 762, 763
and mortality data, 802, 803
and serum cholesterol, 769
and serum creatinine levels, 768
and visual acuity, 766
and pernicious anemia with diabetes, 719, 721
and portal and peripheral vein immunoreactive insulin study, 303
and serum growth hormone and insulin, *529-530
and urinary insulin A chain excretion, 99

ALANINE
and gluconeogenesis, *885
and glucose, 728

ALANINE C-14
incorporation into E. coli protein and insulin, *672

ALBUSTIX, 756

ALCAPTONURIA
and inhibition of glucose oxidase paper tests by reducing metabolites, 337-343

ALCOHOL
and diabetic lipemia and acute pancreatitis, *591
and liver bromsulphalein transport and storage, *531

ALDOSE REDUCTASE
and polyol pathway in aorta and cataracts, *592

ALLOXAN
and bile insulin, *469
in chickens, *886
compared with streptozotocin, 85
and inhibition of adenylcyclase, *593

ALLOXAN DIABETES
and aortic mucopolysaccharides, 639-643
and arterial blood flow to pancreas, 81-84
in arteriosclerotic and nonarteriosclerotic rats, 311-322
histopathologic studies, 324-335
and gluconeogenesis, *135
and glycogen synthesis
and starvation, 916-922
and intestinal absorption of sugars, water and sodium, 683-687
and kidney damage, 33-43
and mucormycosis, 883
and skin acidic glycosaminoglycans, 732-733

AMERICAN DIABETES ASSOCIATION
annual meetings
Thirtieth, 74-75, 140-141, 207, 286-287, 350, 537, 674
Thirty-first, 474, 573, 681, 742, 892
awards
Banting, 675
Lilly, 537, 600, 675, 681, 744, 893
Research and Development, 599-600, 742-744
bylaws, 682
Committees and Editorial Boards for the Organizational Year 1969-1970, 76-77
Diabetes Week, 473, 537, 600, 682, 744
editorial statement on UGDP Study, iii-v
films, 682, 744

FORECAST
"Emotional Side of Diabetes, The," 893
"What Does Sugar in the Urine Mean?," 745
International Diabetes Federation Congress in Buenos Aires, 78
Journess de Diabetologie of the Hotel-Dieu, 144
necrology, 80, 144, 208, 288, 351, 474, 537, 602, 746, 894, 958
new members, 77-78, 208, 351, 601, 745, 958
News of Affiliate Associations, 143-144, 208, 288, 474, 601-602, 745-746, 893, 958
News Notes, 78, 144, 208, 288, 351, 474, 602, 682, 746, 893
personals, 144, 288, 602, 746, 894
postgraduate courses, 75, 80, 141-143, 207-208, 287, 288, 350, 473, 474, 537, 601, 681, 739-742, 891, 954-958
programmed learning text for diabetics, 75
research grants programs, 75, 893
research symposium
ninth, 208, 288, 351, 473, 535, 599, 892
statement on treatment of diabetes, 527

AMERICAN MEDICAL ASSOCIATION
Council on Drugs
statement on UGDP study, vi-vii

AMILORIDE
and hyperkalemia, *887

AMINO ACIDS
assay, 834-835
and cerebral gigantism, *735
composition of proinsulins, 91, 550-552
and gluconeogenesis, *885
incorporation into protein
and insulin, *672
and insulin secretion, 102-107, *136
and glucose, 109-114
intestinal transport
in diabetic rats, *736-737
and maple syrup urine disease, *284
and pancreatic insulin secretion, 217-227
response to insulin, *348
sequence
of proinsulins, 539
transport, *205

DIABETES: VOLUME 19 (1970) PAGE NUMBERS BY ISSUE

January, 1-80
February, 81-144
March, 145-208
April, 209-288
May, 289-352
Supplement 1, 353-408
June, 409-474
July, 475-538
August, 539-602
September, 603-682
October, 683-746
Supplement 2, 747-830
November, 831-894
December, 895-958

AMINOGLUTETHIMIDE
and partially pancreatectomized rats, *884

AMMONIA
production
in renal cortical slices, *952
and renal gluconeogenesis, *735

AMPHOTERICIN B, 883

AMPUTATION
of lower extremity, 189-195
in UGDP study, 756

AMYLASE
test
and pancreatic disease diagnosis, *890

ANEMIA
megoblastic
and orotic aciduria, *592
pernicious
and diabetes, 719-722

ANGIOGRAPHY
in study of diabetic retinopathy and pituitary ablation, 703-714

ANTAGONISTS. *See* Antibodies to insulin; Synalbumin antagonist.

ANTIBIOTICS
and mucormycosis, 883
and perinephric abscess, *953
and serum cholesterol and triglycerides, *889

ANTIBODIES
to insulin, *285
in controlled and resistant diabetics, *205
and insulin radioimmunoassays, 411-414
and pig insulin, *469-470
and proinsulin, 289
insulin-binding
and insulin dosage, 749
and pernicious anemia, 721-722

ARGININE
and growth hormone release, *887-888
growth hormone response to
and growth hormone deficiency in children, *139
infusion
and pheochromocytoma, *344
insulin response to
and 2-deoxy-D-glucose, 453-457
and insulin response to glucose in myotonic dystrophy patients, *134
and insulin secretion, 102-107, 109-114, *136, 477, *734-735
and Cushing's syndrome, *471
and pancreatic glucagon secretion, *200
tolerance test, 493
with insulin tolerance tests, *531-532
in obese adolescents, 495-496

ARTERIES
blood flow to pancreas
and alloxan diabetes, 81-84
calcification
in UGDP study, 767, 770, 771, 783, 799, 800, 802, 803, 810
pulses
in UGDP study, 768, 771, 783

ARTERIOSCLEROSIS
and alloxan diabetes in rats, 311-322, 324-335

L-ASPARAGINASE
diabetogenic effect, *596

ASPIRIN
inhibition of glucose oxidase paper tests, 337-343

ATHEROSCLEROSIS
and chromium deficiency, 115
and corn oil diet, *948
and diabetes, *138
and platelet phospholipids, 698-702
and insulin, *205
and metabolism, *347-348
and mucopolysaccharides, 639

ATROPINE
and insulin response to gastrin, *135

AUTOANALYZER, 4, 23, 46, 110, 196, 756, 798

B

BABOONS
and autonomic blocking agents on, *738

BIGUANIDES
and glucose metabolism, 45-48
and intestinal absorption, *469

BILE
insulin in, *469

BIOTHESIOMETRY
MEASUREMENTS, 757

BLOOD
acetone bodies
in juvenile diabetic, *133
cholesterol, triglycerides, free fatty acids, and glucose
in maturity-onset diabetics, *470-471
circulation
and amputation, 191
flow to pancreas
and alloxan diabetes, 81-84
immunoreactive insulin
and vagotomy and splanchnicotomy in monkeys, *887
insulin
variations in, *671
lactate
and fructose infusion, *344
lipids
and lipemia retinalis, *670
pernicious anemia
and diabetes, 719-722
platelet phospholipids
and diabetes, 698-702
samples
in d-ribose study, 11
in insulin release study, 430
from obese adolescents, 493
in plasma zinc and copper study, 235
in portal and peripheral vein immunoreactive insulin study, 302-306
in UGDP study, 756
triglycerides
and alloxan diabetes, 317
urea nitrogen
and diazoxide analog, 632
and diazoxide therapy, 231

BLOOD GLUCOSE. *See also* Blood sugar.
in children of two diabetic parents, *532
and chlorpropamide-induced hypoglycemia, 930-936
diurnal patterns
in normals and juvenile diabetics, *470
and erythroblastosis fetalis, *470
and exercise and diet, *888
and glibenclamide, *884
and hypophysectomy, 506-507
and insulin
and growth hormone, *593

DIABETES: VOLUME 19 (1970) PAGE NUMBERS BY ISSUE

January, 1-80
February, 81-144
March, 145-208
April, 209-288
May, 289-352
Supplement 1, 353-408
June, 409-474
July, 475-538
August, 539-602
September, 603-682
October, 683-746
Supplement 2, 747-830
November, 831-894
December, 895-958

of pancreatectomized dogs treated with oxytetracycline, 308-310
and pancreatectomy in rat, 695-697
of patients in UGDP study, 748-749, 754-755, 759-762, 780, 781, 800, 804-806, 810, 813
and diabetes diagnosis, 797-798, 863-869
and mortality, 802, 803
percentage distribution by, 761, 762, 763, 764, 765, 767
plasma insulin ratios, 5-6
and plasma insulin response to tolbutamide, *469
and ponderal index
and cancer proneness, *593
in relatives of diabetics, 5
and d-ribose, 11-16
screening method for determining, *138
tests
and diabetes screening, *135
and 2-thiophenecarboxylic acid, *596
and threonine deficiency, *533
and unstable diabetes, 644-655

BLOOD PRESSURE
of patients in UGDP study, 755-756, 763
and diagnosis of hypertension, 798
percentage distribution by, 782

BLOOD SUGAR *See also* Blood glucose.
in aged diabetics, *139
in anencephalic infant, *885-886
capillary, 176-181
and catecholamines, *202
control
in rat and hamster, *951-952
and diabetes diagnosis, 863-869
in diabetes and heart disease survey, 939-940
and diabetic retinopathy, *948
and diazoxide, 229-230
and diazoxide analog, 631
and glibenclamide, 264-270, *532, 580-583
and lactate infusion, *344
of normal and diabetic pregnant rats, 611
in normal subjects, 854
and pituitary stalk section, *591
and plasma insulin
circadian variations of, *530-531
and propranolol therapy, *468
of rabbits in serum insulin study, 156
response to stimulation of endogenous secretin release, *72
serum insulin and free fatty acids during intravenous tolbutamide testing, 122-126
and serum insulin response, *134
tests, 666
and diabetes screening, *471
"instant," 724-726
and vagotomy or splanchnicotomy in monkeys, *887

BLOOD VESSELS
capillaries
blood sugar values during glucose tolerance tests, 176-181
dilation in diabetic retinopathy, 706-707
displacement of insulin from, *472
eye reactivity and ultrastructure study, *528-529
nailfold and hypertriglyceridemia, *886
skeletal muscle in diabetics, *890
skeletal muscle in nondiabetics, *890

BODY
bilateral foot-drop, *472
composition
and diet, *597
extremities
and mucormycosis, 881-883
fat
and lipid mobilization, *283
forearm
proinsulin metabolism study, *885
growth
and antileukemic therapy, *533-534
and Cockayne's syndrome, *595
and gonadal dysgenesis, *595
and tolbutamide, 604
head injury
and glucose tolerance, *596
joints
multiple neuropathy, *470
legs
and diabetic gangrene, *138
lower extremities
amputation, 189-195
X-rays, 756
organs and tissues
role in glucose assimilation, *528
potassium
in malnourished children, *734
surface
and insulin dosage, 749, 773
temperature
and hypoglycemia, *205-206
weight
and diet, 749-750
and glucose metabolism, *204
and hyperzincuria, 244
and insulin and growth hormone responses, 492-500
of maturity-onset diabetics, *470-471
of patients in UGDP study, 755, 763, 765, 770, 773, 798, 800, 802, 803, 810
of relatives of diabetics, *736
weight reduction
and bulking agents, 63, 69

BOOK REVIEWS
Clinical Endocrinology, by J. Anderson and G.A. Smart, 527
Diabetes and the Eye, by F.R. Caird, A. Pirie, and T.G. Ramsell, 734
Duncan's Diseases of Metabolism, Vol. I: Genetics and Metabolism. Vol. II: Endocrinology and Nutrition, edited by Philip K. Bondy, 527-528
Galactosemia, edited by David Yi Yung Hsia, 281
Hyperlipidemia & Hyperlipoproteinemia, by Shafeek S. Sanbar, 281
New Management of Stable Adult Diabetes, edited by Charles Weller, 281
Oral Hypoglycemic Agents: Pharmacology and Therapeutics, by G.D. Campbell, 132
Protein and Polypeptide Hormones, edited by M. Margoulies, 132
Sustained Weight Control: The Individual Approach, by T.S. Danowski, 734

BRAIN
and glucose consumption, *284, *885-886
and malnutrition, 486
during sleep
and growth hormone release, *73

BROMSULPHALEIN
storage and transport
and diabetes and alcoholism, *531

C

CAFFEINE
and alloxan inhibition and insulin release, *593

DIABETES: VOLUME 19 (1970) PAGE NUMBERS BY ISSUE

January, 1-80
February, 81-144
March, 145-208
April, 209-288
May, 289-352
Supplement 1, 353-408
June, 409-474
July, 475-538
August, 539-602
September, 603-682
October, 683-746
Supplement 2, 747-830
November, 831-894
December, 895-958

CALCIUM
deficiency, 49, 52
excretion during glucose and mercaptomerin diuresis, *672
and insulin secretion, 902
magnesium antagonism
and insulin secretion, *528

CALORIES
intake
and hypoglycemia in children, *205
plasma triglyceride response to, *736
in UGDP study, 749-750, 754

CANDIDA MENINGITIS
and adrenal insufficiency
and juvenile diabetes, 438-441, 443-444

CARBAMAZEPINE
and diabetic neuropathy, *137

CARBOHYDRATES
and body composition, *597
intolerance
and fasting, *952-953
and gout, *345
and heart disease, *598
and pheochromocytoma, *344
loading
and diabetes diagnosis, 863-869
and growth hormone, 196-199
metabolism
and fasting, 692
and fetal mortality, *673
in fetal rhesus monkey muscle, *344
and liver cirrhosis, *949-950
in relatives of diabetics, 1-9
plasma triglyceride response to, *736
tolerance
and false sugar diabetes, *345
and pituitary stalk section, *591
and uremia, *889

CARCINOMA
breast
and pituitary stalk section, *591
islet cell, *134
liver
and hypoglycemia, *348
proneness profile, *593
in UGDP study, 827-830

CARDIOTHORACIC RATIO
in UGDP study, 782
by age and sex, 769

CARDIOVASCULAR DISEASE. *See also* Heart disease.
in aged diabetics, *139
and glucagon infusion, *738
in UGDP study
characteristics, 764-768
family history, 778
history, 758-759
and mortality, 790-792
risk factors, 710, 770, 783, 799, 800, 802, 803

CASE REPORTS
anacidotic hyperglycemia and focal seizures, *594
Candida meningitis and adrenal insufficiency in juvenile diabetes, 438-441, 443-444
cerebral edema during diabetic coma, *284
cerebral edema and nonketotic hyperglycemia, *204
cerebral gigantism, *735
chlorpropamide and diabetes insipidus, *949
chlorpropamide-induced hypoglycemia, *672, 930-933
clinical remission in diabetes, 116-117
Cockayne's syndrome, *595
coexistent diabetes mellitus and insipidus and optic atrophy, *949
cutaneous reaction to insulin injections, *201-202
diabetes and Addison's disease, *134
diabetes and esophageal motor manifestations, *738
diabetes in identical twins, 878-880
diabetes insipidus in children and chlorpropamide therapy, *885
diabetes and plasma insulin levels, *597
diabetic ketosis and SGOT tests, 730-731
diabetic lipemia and acute pancreatitis, *591
diabetic retinopathy and photocoagulation, *948-949
extrapancreatic tumor hypoglycemia, 248-250
factitious hypoglycemia, *593-594
glucagon infusion in treatment of cardiovascular disease, *738
glybenclamide therapy, 579-581
hemochromatosis, *285
hereditary orotic aciduria and uridine therapy, *592
hyperglycemia and hyperosmolarity in brittle diabetes with thyrotoxicosis, 70-71
hyperglycemic, hyperosmolar, nonketotic coma, *348
hyperglycemic coma and corticosteroid therapy, *471-472
inhibition of glucose oxidase paper tests by reducing metabolites, 337-343
insulin resistance and transplantation of pancreatic insulinoma, 182-184
insulinoma in childhood, *204
insulinoma and diazoxide administration, *948
ketone infusion in ketotic hypoglycemic children, *673
lactic acidosis in diabetes, *670
lipodystrophy, *202
liver cirrhosis, *949-950
McCune-Albright, syndrome, *886
mediastinal and subcutaneous emphysema in diabetic coma with vomiting, *201
mucormycosis and gangrene, 881
multiple neuropathic joints, *470
myotonia dystrophica and insulin response, *471
perinephric abscess and diabetes, *953
renal papillary necrosis, *470
scleredema and diabetes, *735, *884
spontaneous disappearance of insulin-resistant diabetes, *884
Zollinger-Ellison syndrome, *284

CASEIN
and insulin secretion, 217-227

CATARACTS
and polyol pathway in aorta, *593

CATECHOLAMINES
and hypoxia and insulin levels, *592
and insulin secretion
and alpha adrenergic blocking agents, 688-692
and plasma free fatty acids and blood sugar in birds, *202
release
and diazoxide, 637

CENTRAL AMERICA
diabetes survey in, 656-662

CHELATING AGENTS
and hyperzincuria, 246

DIABETES: VOLUME 19 (1970) PAGE NUMBERS BY ISSUE

January, 1-80
February, 81-144
March, 145-208
April, 209-288
May, 289-352
Supplement 1, 353-408
June, 409-474
July, 475-538
August, 539-602
September, 603-682
October, 683-746
Supplement 2, 747-830
November, 831-894
December, 895-958

CHI-SQUARE TESTS
of UGDP study mortality results, 793, 800

CHICKEN
insulin action in, *886-887

CHILDREN
with cerebral gigantism
amino acid study in, *735
and Cockayne's syndrome, *595
with cystic fibrosis
and serum insulin levels, *348
with diabetes insipidus
and chlorpropamide therapy, *885, *953
diabetic
calorie requirements, *673
with diabetic acidosis
and liver function, *888
of diabetic parents, *532
with glucocorticoid-induced growth retardation
and growth hormone secretion and metabolism, *673
glucose tolerance tests in
and capillary blood sugar values, 176-181
growth hormone deficiency in, *139
with heat stroke
and hyperglycemia and acidosis, *531
with immunologic defects
and disaccharidase deficiency, *951
insulin patterns in, *529
with insulinoma, *204
ketotic hypoglycemia in
and gluconeogenesis and insulin, *205
and ketone infusion, *673
leukemic
growth study in, *533-534
malnourished
body potassium, muscle electrolytes, and glycogen in, *734
with McCune-Albright syndrome, *886
with nephrotic syndrome
and plasma lipoprotein lipase, *530
obese
and growth hormone response to oral glucose, *138
and insulin and growth hormone responses, 492-500
and metabolic response to epinephrine and propranolol, *204
phenylketonuric
and plasma growth hormone after phenylalanine tolerance tests, *593
with primary hypothyroidism and thyrotoxicosis
and growth hormone release and growth, *72
with untreated diabetes
and plasma insulin and growth hormone levels, *890

CHLORPROMAZINE
and glucose tolerance, 186-188

CHLORPROPAMIDE
and diabetes insipidus, *528, *885, *949, *953
and glibenclamide, 583
-induced hypoglycemia, *672, 930-936
site of action of, *134
and streptozotocin diabetes, 90

CHOLECYSTOKININ-PANCREOZYMIN
insulin-like effects, *951
synthesis of C-terminal dodecapeptide of, *737

CHOLINERGIC BLOCKADE
and growth hormone response to insulin hypoglycemia, *133

CHONDROITIN SULFATES, 167
synthesis
and alloxan diabetes, 639-643

CHROMATOGRAPHY
column
in glucagon-like immunoreactivity study, 615
and desalting of urine, 98-99
gas-liquid
of diabetic kidney tissue, 163
in glucagon-like immunoreactivity study, 617-622
paper
of kidney tissues in glycoprotein study, 172, 173
thin layer
of hyperlipemia, *953

CHROMIUM
and serum cholesterol, 115

CLINISTIX TESTS
inhibition by reducing metabolites, 337-343

CLINITEST, 755
inhibition by reducing metabolites, 337-343

CLOFIBRATE
and serum cholesterol and triglycerides, *889

COCKAYNE'S SYNDROME, *595

COLCHICINE
and insulin secretion, 902

COLLAGEN
synthesis
and insulin, 465-466

COMA, *283
and cerebral edema, *284
and emphysema and vomiting, *201
hyperglycemic
and corticosteroid therapy, *471-472
hyperglycemic, hyperosmolar, nonketotic, 70-71
in ketosis-prone juvenile diabetic, *348
and lactic acidosis, *670
nonketotic diabetic, *344

CONGENITAL DEFECTS
and tolbutamide therapy during pregnancy, *594-595

CONVULSIONS
and Candida meningitis and diabetes, 438-439

CORI CYCLE
and phenformin therapy in nondiabetic humans, *349

CORONARY DISEASE. *See* Cardiovascular disease; Heart disease.

CORTICOSTEROIDS
and glucose and lactate metabolism, 61
and hyperglycemic coma, *471
and splanchnomegaly, *884
topical
response of intraocular pressure to, 715-718

CORTISOL
anti-insulin action of, *471
and insulin secretion in fasted mice, *885
and metabolism, *284
-stimulated gluconeogenesis, *672

CORTISONE
as diabetic stimulus, 196-199
-glucose tolerance tests in "nondiabetic" relatives of diabetics, 1-9
and hyperglycemia and glucosuria in guinea pigs, 145

DIABETES: VOLUME 19 (1970) PAGE NUMBERS BY ISSUE

January, 1-80
February, 81-144
March, 145-208
April, 209-288
May, 289-352
Supplement 1, 353-408
June, 409-474
July, 475-538
August, 539-602
September, 603-682
October, 683-746
Supplement 2, 747-830
November, 831-894
December, 895-958

CUSHING'S SYNDROME
and insulin secretion
and glucose and arginine, *471

CYCLAMATES
and skin sensitivity to sunlight, 479, 501, 623

CYCLOHEXYLAMINE
and cyclamate ingestion, 623

CYCLOPHOSPHAMIDE
and growth, *533

CYSTIC FIBROSIS
and serum insulin levels, *348

D

2-DEOXY-D-GLUCOSE
and glucose utilization, *533
and insulin response to glucose, glucagon, tolbutamide, and arginine, 453-457

2-DEOXYGLUCOSE
and diabetic ketosis, 521

DEXAMETHASONE
topical
response of intraocular pressure to, 715-718

DEXTROSTIX
in "instant" blood sugar test, 724-726

DIABETES INSIPIDUS
and chlorpropamide therapy, *528, *885, *949, *953
and chlorpropamide and vasopressin, *134
and chlorpropamide-induced hypoglycemia, *672
and diabetes mellitus
and optic atrophy, *949

DIABETES MELLITUS
and acetohexamide and potassium, *134
and acid mucopolysaccharide composition of kidney, 161-169
and Addison's disease, *134
in aged patients, *139
and amiloride
and hyperkalemia, *887
and amputation of lower extremities, 189-195
and aortic mucopolysaccharides, 639-643
and atherosclerosis, *138
and basement membrane changes, *949
and bilateral foot-drop, *472
and brain metabolism in rats, *284
"brittle"
and insulin-induced post-hypoglycemic hyperglycemia, *592
with thyrotoxicosis, 70-71
and chromium deficiency, 115
and coma, *344
and congenital abnormalities in children, *953
and conjunctival vascular lesions, *950
control
and insulin antibodies, *205
and coronary heart disease, *597-598
detection
and glucose-fucose response, *887
and diabetes insipidus
and optic atrophy, *949
diagnosis
and evaluation of glucose tolerance tests, *136, 870-877
and fasting, *345
and serum insulin responses, *529
and serum lipids, *736
and size and nature of carbohydrate load, 863-869
UGDP criteria for, 750, 758-759, 769, 797-798, 812
and dialysis, *345
and diet
high carbohydrate, *137
in sand rat, *468
and erythrasma, *348
and esophageal motor function, *738
etiology, *349
and glucose intolerance and insulin resistance, *201
and gangrene, *138
and glaucoma
and interocular pressure response to topical corticosteroids, 715
and glucose and fat metabolism, *889
and glucose loading
and serum fucose levels, *887
and glybenclamide, 579-584, *884
and gout, *345
and growth hormone
and glucose, *345-346
and heart disease, *203
and hemochromatosis, *285
and hemorrhagic glaucoma, 944-947
and heredity, 1-9, *530
and human crystalline insulin, *344
and hypophyseal function, *534
in identical twins, 878-880
and insulin
and growth hormone secretion, *472
and insulin A-chain excretion in urine, 98-101
insulin-resistant
spontaneous disappearance of, *884
and insulin secretion, *73
and enteric hormones, *886
juvenile
and adrenal insufficiency and Candida meningitis, 438-441, 443-444
and beta adrenergic blockade, *201
and chlorpropamide-induced hypoglycemia, *672
and coma, *348
control, *133
and corn oil diet, *948
and diet, *673
and diurnal patterns of blood glucose, serum free fatty acids, insulin, glucagon and growth hormone, *470
and immunoreactive insulin and serum insulin, *139
and insulin resistance, 182-185
in Israeli Jews, 585-590
and platelet phospholipids, 698-702
and serum lipids and lipoproteins, *345
and ketoacidosis, *344
and ketoacidosis and hyperlipidemia, *951
and ketosis
and stress, 692
and kidney, *470
and glycoprotein changes, 171-175
and Klinefelter's syndrome, *597
and lactic acidosis, *344, *670
and Laennec's cirrhosis, *671
and liver bromsulphalein transport and storage, *531
and liver mitochondria changes, *531, *592
and liver structure and function, *534
maternal
and infants, *139
maturity-onset
and blood cholesterol, triglycerides, free fatty acids, glucose, and body weight, *470-471
etiology, *285
and glucose tolerance tests in relatives, *347
and oral hypoglycemic agents. *See* UGDP study.

DIABETES: VOLUME 19 (1970) PAGE NUMBERS BY ISSUE

January, 1-80
February, 81-144
March, 145-208
April, 209-288
May, 289-352
Supplement 1, 353-408
June, 409-474
July, 475-538
August, 539-602
September, 603-682
October, 683-746
Supplement 2, 747-830
November, 831-894
December, 895-958

and platelet phospholipids, 698-702
and metapyrone and aminoglutethimide, *884
mild
and serum insulin response to glucose, 458-463
and mucormycosis and gangrene, 881-883
and multiple neuropathic joints, *470
and obesity
and hypothalamic satiety center, *594
and oxytetracycline treatment, 310
and pancreas glucagon secretion, *200
and parabiosis, *671
and perinephric abscess, *953
and pernicious anemia, 719-722
and phenformin, 64-68
and pheochromocytoma
and urinary catecholamines, 691
and plasma insulin A-chain response to glucose loading, *136
and plasma insulin concentration
and glucose uptake, 571-577
and plasma insulin levels, *597
and plasma and urine insulin, *135
and plasma zinc and copper, 234-238
prevalence
in Central America, 656-662
and race, *532
remittent, 116-121
and d-ribose, 11-16
and scleredema, *735, *884
screening, *135
and growth hormone, 196-199
and serum lipids, *736
and serum lipids and lipoproteins, *595
and serum zinc, *532
and skeletal muscle capillaries, *890
and standardization of terminology, 664-668
of starvation, *738
streptozotocin-induced
and fetal pancreatic insulin content, 610-613
subclinical
in relatives of diabetics, 1-9
and sulfate-35 uptake and incorporation into aortic mucopolysaccharides, *593
and surgery, *598
and tolbutamide administration, *533
surveys
in Israel, 938-943
in Oxford, Massachusetts, *137
in Zagreb, *471
and synalbumin, *670
and testosterone, *134
and tolbutamide therapy. *See* UGDP study.
"transient," *595
transient neonatal, *885
treatment
drug-placebo comparisons. *See* UGDP study.
and pig insulin, *469-470
unstable
and hypoglycemia and hyperglycemia, 644-655
and urinary zinc levels, 240-246
and urine diabetogenic peptide, *204
and urine glucosamine acetoacetate condensate, *531
and vascular complications
and personality, 259-263
and vascular disease, 311-322
and insulin, *205

DIALYSIS
in diabetics, *345

DIARRHEA, *206
and pentose ingestion, 24

DIAZOXIDE
and acute diabetic ketoacidosis, *73
analogs
and insulin secretion, 630-638
and insulin secretion, 271-280
and glybenclamide, *282
and insulinoma, *948
and metabolism
and beta adrenergic blockade, 228-232

DIBUTYRL CYCLIC AMP
and theophylline
and antilipolytic agents, *593

DICHLORISOPROTERENOL
and adenylcyclase activity in fat cells, *673

DIET
and amino acid imbalance, *531
and animal experiments, 49, 52
and body composition, *597
and calorie requirements of juvenile diabetics, *673
corn oil
and plasma cholesteryl esters, *948
and cyclamates, 479, 501, 623
and decreased glucose utilization, *533
and exercise
and plasma insulin and blood glucose, *888
and false sugar diabetes, *345
high carbohydrate
and diabetes treatment, *137
and hypoglycemia in children, *205
iron enrichment, 419
and islet cell carcinoma, *134
low-chromium, 115
and maple syrup urine disease, *284
and metabolic effects of pancreatectomy in rat, 695-696
in plasma insulin response studies in animals, 17
and plasma triglyceride response, *736
powdered formula for infants, *595
and precursors of heart disease, *598
of sand rats
and diabetes, *468
sugar
and coronary heart disease, *73, 923, 929
sweetening agents, 718
stevioside, 841
threonine-devoid
and blood glucose and hepatic glycogen, *533
and tolbutamide. *See* UGDP study.
in UGDP study, 749-750, 754, 789
and unstable diabetes, 645
weight-reducing
and bulking agents, 63, 69

DIGITALIS
in UGDP study, 770, 783, 799, 810
and chi-square tests of distribution, 800
and mortality, 802, 803

DIHYDROSTEVIOL, 841

DIHYDROXYPHENYLALANINE
and inhibition of glucose oxidase paper tests, 337-343

DI-ISOPROPYLAMMONIUM DICHLOROACETATE
and glucose and fat metabolism, *889

DIPHENYLHYDANTOIN
and insulin secretion, *952

DISACCHARIDASE
deficiency
in children with immunologic defects, *951

DISCHE CARBAZOLE METHOD, 162-163

DIABETES: VOLUME 19 (1970) PAGE NUMBERS BY ISSUE

January, 1-80
February, 81-144
March, 145-208
April, 209-288
May, 289-352
Supplement 1, 353-408
June, 409-474
July, 475-538
August, 539-602
September, 603-682
October, 683-746
Supplement 2, 747-830
November, 831-894
December, 895-958

DOGS
with allografted pancreas, *346-347
beta-adrenergic stimulation and insulin release in, *137-138
carbohydrate intolerance and fasting in, *953
diazoxide hyperglycemia in, 230-231
exercise, insulin and glucose turnover in, *138
glucagon-like immunoreactivity in, 614-622
growth hormone and glucose metabolism study in, 487-491
growth hormone and insulin utilization in, *593
hypoxia and insulin level study in, *592
insulin release and glucagon study in, 429-436
insulin secretion and hyperketonemia in, *953
interruption of arterial blood flow to pancreas in, 83
pancreatectomized
and oxytetracycline treatment and insulin response, 307-310
plasma insulin response after xylitol, glucose or tolbutamide infusion in, 17-22
renal gluconeogenesis and ammonia production in, *735
streptozotocin diabetes in, 85
xylitol-induced insulin secretion in, *135-136

DUCK
plasma free fatty acids and blood sugar
and catecholamines, *202

E

ELECTROCARDIOGRAMS
and glucose ingestion, *201
of patients in UGDP study, 756, 770, 782, 798, 799, 810
and cardiovascular risk factors, 764
and mortality, 802, 803

ELECTROENCEPHALOGRAMS
and growth hormone release study, *73

ELECTROPHORESIS
in diabetic kidney tissue study, 163
disc
in insulin isolation technics, 833
of hyperlipemia, *953
of kidney tissue
in study of glycoprotein changes, 172
paper
and binding of zinc to insulin, *949
polyacrylamide gel
in glucagon-like immunoreactivity study, 616, 621
in insulin antibody assays, *205

EMPHYSEMA
mediastinal and subcutaneous
and diabetic coma, *201

ENDOCRINE GLANDS
function
and hypophysectomy, 304-305
insufficiency
after transethmoido-sphenoidal hypophysectomy, 509-510

ENZYMES
and inhibition of adenylcyclase by alloxan, *593

EPILEPSY
focal
and anacidotic hyperglycemia, *594

EPINEPHRINE
and adenyl cyclase activity in fat cells, *673
and amino acid
and insulin secretion, 218-227
glucose, free fatty acid, and insulin responses to
and nonpancreatic tumors, 250-251
and glycerol release
and B-hydroxybutyrate, *595
and insulin action
and alpha adrenergic blockade, 692
and insulin release, 429, 480-485
and lipolysis
and insulin and proinsulin, 209-216
and plasma free fatty acids and blood sugar, *202
and plasma insulin response to xylitol, glucose, or tolbutamide infusion, 17-22
release
and hypoglycemia, 688
response
in obese adolescents, *204
and oxytetracycline, 308-310
and Sotos' syndrome, *72
and sorbitol content of aortic wall, *593
topical
and conjunctival microaneurysms, *528-529

ERGOTAMINE TARTRATE
and epinephrine suppression of insulin release, *136

ERYTHROBLASTOSIS FETALIS
and serum insulin, *470

ESCHERICHIA COLI
alanine C-14 and leucine C-14 incorporation into
and insulin, *672

ESOPHAGUS
and diabetes, *738

ESTRADIOL
and insulinemia, *133

ETHANOL
and heart metabolism and function, *596
and liver metabolism and glucose, *470

N-ETHYLMALEIMIDE
and lipolysis, *670

EXERCISE
and blood glucose and plasma insulin, *888
and insulin and glucose turnover in dogs, *138
and lipolysis, *133
and unstable diabetes, 645

EYE. *See also* Retinopathy; Vision.
atrophy
and diabetes mellitus and insipidus, *949
conjunctival microaneurysms
and topical epinephrine, *528-529
and diabetic hemorrhagic glaucoma, 944-947
examinations in UGDP study, 755
intraocular pressure response to topical corticosteroids
and glucose tolerance, 715-718

F

FAMILY HISTORY
and age of diabetes onset, *530
and cortisone glucose tolerance tests in "nondiabetic" relatives of diabetics, 1-9

DIABETES: VOLUME 19 (1970) PAGE NUMBERS BY ISSUE

January, 1-80
February, 81-144
March, 145-208
April, 209-288
May, 289-352
Supplement 1, 353-408
June, 409-474
July, 475-538
August, 539-602
September, 603-682
October, 683-746
Supplement 2, 747-830
November, 831-894
December, 895-958

of diabetes and cardiovascular disease in patients in UGDP study, 759, 778
and glucose tolerance tests, *347
and hyperzincuria, 240-246
in juvenile diabetes survey in Israel, 586-590
and lipemia retinalis, *670
and obesity, *137
and pernicious anemia with diabetes, 719-720
and portal and peripheral vein immunoreactive insulin study, 303
and serum lipids, *952
and serum lipids, body weight, and glucose tolerance, *736
and standardization of terminology in diabetes, 664-668
and urinary A chain excretion, 99

FASTING. *See* Starvation.

FATTY ACIDS
free
and adrenergic blocking agents, *738
and blood sugar and serum insulin during tolbutamide testing, 122-126
and glucose uptake, 692
and growth hormone, 196-199
and insulin in fasting pregnant rats, 563-570
and insulin secretion, *950
and liver cirrhosis, *592
and nonpancreatic tumors, 250-251
and obesity, *283
and starvation, *885, *953
and 2-thiophenecarboxylic acid, *596
nonesterified
circadian variations in, *530-531
during imaginary food intake, *735
oxidation
in diabetic rat liver, *202
in rat brain
and malnutrition, 486
synthesis
and chromium, 115
uptake
and fasting hypophysectomy, 924-928

FETUS
of healthy mothers
pancreatic proinsulin content of, *888
insulin levels, *737
insulin response
and maternal glucose administration, *534
mortality
and diabetic pregnancy, *673, *884
pancreas
and beta cell response to glucose, 506-514
insulin content and streptozotocin diabetes, 610-613

FLUORESCEIN ISOTHIOCYANATE
in proinsulin study, 539-540, 544-545

FLUOXYMESTERONE
and gonadal dysgenesis, *595

FOOD AND DRUG ADMINISTRATION
statement on oral hypoglycemics, x-ix
statement on usage of tolbutamide, 467-468

FRUCTOSE
and bile insulin, *469
infusion
and blood lactate, *344
and insulin release, *953
metabolism
and cortisol, *284

D-FRUCTOSE
serum insulin response to, 155-160

FUNDUS PHOTOGRAPHS
in UGDP study, 755, 766, 771, 783
reading code, 776

G

GALACTOSE
and bile insulin, *469
metabolism
and cortisol, *284
and sodium pump, *591-592
urinary
in newborn infants, *529

D-GALACTOSE
intestinal absorption of
and alloxan diabetes, 683-687
serum insulin response to, 155-160

GALACTOSEMIA
screening tests, *529

GANGRENE, *138
in aged diabetics, *139
and amputation, 189-195
and mucormycosis and diabetes, 881-883

GASTRIN
C-terminal tetrapeptide amide
and insulin secretion, *135, *597
and Zollinger-Ellison syndrome, *284

GASTROINTESTINAL TRACT
absorption, 48
and metformin therapy, *469
absorption of sugars, water and sodium
and alloxan diabetes, 683-687
and diabetic diarrhea, *206
glucagon-like immunoreactivity, 614-622
glucose absorption
and acetylsalicylic acid, *205
and insulin release, 692
glucose transport
and phenformin, 50-52
and insulin release, *950
and pentose ingestion, 24
and phenformin, 45
portocaval shunts, *952
sodium pumps
and hexose transfer and metabolism, *591-592
sugar and amino acid transport
in diabetic rats, *736-737
sugar and sodium transport, *72

GEESE
plasma free fatty acids and blood sugar
and catecholamines, *202

GENES. *See also* Heredity.
and amino acid metabolism, *205
and diabetes, 835
and hyperzincuria, 240-246
and intraocular pressure response to topical corticosteroids, 715
and streptozotocin response, 90

GIGANTISM
cerebral, *72
and plasma and muscle amino acids, *735

GLAUCOMA
and diabetes, 715, 944-947
steroid-induced, *202

GLIBENCLAMIDE, *136. *See also* Glybenclamide
and beta-adrenergic stimulation of insulin release in dogs, *137-138
evaluation of, *532
metabolic and clinical effects, *884

GLUCAGON
and adenyl cyclase activity in fat cells, *673
in commercial insulin, 29

DIABETES: VOLUME 19 (1970) PAGE NUMBERS BY ISSUE

January, 1-80
February, 81-144
March, 145-208
April, 209-288
May, 289-352
Supplement 1, 353-408
June, 409-474
July, 475-538
August, 539-602
September, 603-682
October, 683-746
Supplement 2, 747-830
November, 831-894
December, 895-958

and glucagon-like immunoreactivity
molecular size of, 624-629
glucose, free fatty acid, and insulin responses to
and nonpancreatic tumors, 250-251
and glucose metabolism
in goosefish islet, 554-57
and hypocalcemia, *206
infusion
and cardiovascular disease, *738
and insulin release, 420-428, 429-436, *886
and 2-deoxy-D-glucose, 453-457
in premature infants, 837-840
in thyrotoxicosis and primary myxedema, *468-469
and islet cell carcinoma, *134
-like immunoreactivity, 614-622
and lipolysis, 91-97
and liver phosphorylase activity, *349
pancreatic secretion in diabetics and normals, *200
and plasma free fatty acids and blood sugar, *202
and remittent diabetes, 116-121
responses
and pheochromocytoma, *598
self-association of, *73
and urinary cyclic AMP and cyclic GMP excretion, *530

GLUCOCORTICOIDS
and Cushing's syndrome, *471
-induced growth retardation
and growth hormone studies, *673

GLUCOLA
and diabetes diagnosis, 863-869

GLUCONEOGENESIS
and alanine, *885
and carbohydrate metabolism
and fasting, 692
cortisol-stimulated
assay, *672
and diabetic acidosis, 728
and ketone infusion, *673
and ketotic hypoglycemia in children, *205
in normal and obese humans, 53-62
and obesity
and phenformin, 64-68
renal and hepatic
in alloxan diabetic and starved animals, *135

GLUCOSE
absorption
and acetylsalicylic acid, *205
administration
in anencephalic infant, *885-886
in fasted pregnant and nonpregnant rats, 566
fetal insulin response to, *534
and pheochromocytoma, *344
and adrenergic blocking agents, *738
and amino acids
and insulin secretion, 217-227
and ammonia production, *735
in renal cortical slices, *952
assimilation, *529
and beta cell response, 906-914
and bile insulin, *469
disappearance rates
and pituitary stalk section, *591
disposal
and liver, *530
diuresis
calcium and magnesium excretion during, *672
and growth hormone, *888
and diabetes, *345-346
in obese children, *138
and hexokinase synthesis, *735
-induced insulin secretion
and adrenergic receptors, *201
infusion
in infants of diabetic mothers, *203
and portal and peripheral vein immunoreactive insulin, 302-306
ingestion
and electrocardiogram changes and serum potassium values, *201
and glucagon-like immunoreactivity, 614-622
and insulin release, 561-562
and 2-deoxy-D-glucose, 453-457
and obesity and mild diabetes, 458-463
and race, *532
and thyrotoxicosis and primary myxedema, *468-469
and insulin secretion, 903
and amino acids, 109-114
and Cushing's syndrome, *471
and fasting, 688
and mannoheptulose, 420-428
from rat pancreas, *133
and serotonin, 475-478
intolerance
and growth hormone and insulin levels, *284
and head injury, *596
and liver disease, *201
after starvation, 692, *737-738
labeled
and cortisol, *471
-lactate relationships
and starvation, 53-63
and lipoprotein synthesis, *530
and liver metabolism
during ethanol oxidation, *470
loading
in diabetes survey, 657-658
in normal subjects, 842-850
plasma insulin A-chain response to, *136
and serum fucose levels, *887
malabsorption
and metformin therapy, *469
metabolism
in brains of diabetic rats, *284
of brown fat cells, "bound" insulin and, *887
and cortisol, *284
and diet, 52
and growth hormone, 487-491
and hyperglycemia, tolbutamide and glucagon, 554-557
and nonpancreatic tumors, 248, 251-257
and phenformin, 45-48, 64-68
and proinsulin and insulin, 209-216
in rat epididymal fat tissue, *472
plasma insulin response to, 17-22
in myotonic dystrophy patients, *134
regulation
and intravenous tolbutamide test, *950-951
tolerance. *See* Glucose tolerance
tolerance tests. *See* Glucose tolerance tests
transport by rat intestine
and phenformin, 50-52
turnover
and exercise and insulin in dogs, *138
and phenformin in nondiabetic humans, *349
uptake
and adipose tissue cells, *887
and plasma insulin concentration, 571-577
urinary
and alloxan diabetes, 315-316
utilization
decreased, *533
and growth hormone, 519
and potassium, *134

GLUCOSE LACTATE
metabolism
in rat brain, *202

DIABETES: VOLUME 19 (1970) PAGE NUMBERS BY ISSUE

January, 1-80
February, 81-144
March, 145-208
April, 209-288
May, 289-352
Supplement 1, 353-408
June, 409-474
July, 475-538
August, 539-602
September, 603-682
October, 683-746
Supplement 2, 747-830
November, 831-894
December, 895-958

GLUCOSE OXIDASE, 18
inhibition by reducing metabolites, 337-343

GLUCOSE TOLERANCE
and chlorpromazine, 186-188
and cystic fibrosis, *348
and diabetes, 880
and diazoxide analog, 634
ethnic variabilities in, *532
and infants of diabetic mothers, *950
and liver cirrhosis, *592
mathematical model for analysis of, 445-449
during menstrual cycle, 450-452
and myocardial infarction, *347
and oral contraceptives, *133, *889, *951
in pregnant rhesus monkeys, *888
and propranolol therapy, *468
in relatives of diabetics, *736
and serum lipids, *952

GLUCOSE TOLERANCE TESTS
and amylase levels
in pancreatic disease diagnosis, *890
capillary blood micro technic for, 176-181
comparison of 50 and 100 gram, 852-862
and diabetes diagnosis, *136, 797-798, 863-869, 942
and diazoxide, *948
equivocal, 524-526
evaluation methods compared, 870-877
and gout, *345
and growth hormone, 196-199
in identical twins, 878-880
in infants of diabetic mothers, *950
and intraocular pressure response to topical corticosteroids, 715-718
and nonpancreatic tumors, 250
in normal subjects, 842-850
in obese adolescents, 493
in oral contraceptive users, *889
in phenformin study, 46-48
in relatives of diabetics, 1-9, *347
in remittent diabetes, 117-118
serum glucose and immunoreactive insulin during, *206
in UGDP study, 751, 759-762, 780, 804-805
and diabetes diagnosis, 760
distribution of patients by, 761, 763
SHORT, 754-755
SUM, 754, 769-770

GLUCOSE-I-C-14
conversion to C-14-O_2
and proinsulin, 290, 293-294
disposal
and liver, *530

GLUCOSE-6-C-14, 555-557

GLUCOSE-6-PHOSPHATASE
and pancreas islets, *534

GLUCOSE-6-PHOSPHATE
and cortisol, *471

D-GLUCOSE
uptake by adipose tissue cells, *887

GLUCOSURIA
and cortisone, 145
and negative urinary glucose oxidase test, 337-343
and steroid diabetes in guinea pigs, 148

GLUTAMATE
and ammonia production, *735

GLUTAMIC OXALOACETIC TRANSAMINASE
and alloxan diabetes, 317

GLUTAMIC PYRUVIC TRANSAMINASE
and alloxan diabetes, 317

GLUTAMINE
and ammonia production, *735

GLYBENCLAMIDE
evaluation of, 264-270, *282-283, 579-584

GLYBURIDE
and pancreas beta cells, 605

GLYCEROL
release
and B-hydroxybutyrate, *595
and starvation, *885

GLYCINE
-valine ratio
in cerebral gigantism, *735

GLYCOGEN
C-14 incorporation into
and tolbutamide and glucagon, 557
in liver of diabetics, *534
in muscle of malnourished children, *734

GLYCOGEN PHOSPHORYLASE
in rat muscle, *137

GLYCOGEN STORAGE DISEASE
screening procedure for, *202

GLYCOGEN SYNTHETASE
in rat muscle, *137

GLYCOLYSIS
and ethacrynic acid, *671

GLYCOPROTEINS
in diabetic kidneys, 171-175

GLYCOSAMINOGLYCANS
and skin scleredema, *735

GLYCOSURIA
in alloxan diabetic rats, 325
in juvenile diabetes, *133

GOLD THIOGLUCOSE
and hypothalamic satiety center and insulin, *594

GOLDEN HAMSTER
blood sugar control in, *951-952
pancreas insulin release
and epinephrine and serotonin, 480-485
and serotonin, 475-478

GONADAL DYSGENESIS
and gluoxymesterone, *595

GOOSEFISH
islets
glucose metabolism study, 554-557

GOUT
and carbohydrate intolerance, *345

GROWTH
and Cockayne's syndrome, *595
and gonadal dysgenesis, *595
and growth hormone, *139, *673
and long-term antileukemic therapy, *533-534
and tolbutamide, 604

GROWTH HORMONE
in anencephalic infant, *885-886
and carbohydrate intolerance in pheochromocytoma, *344
deficiency
in children, *139

DIABETES: VOLUME 19 (1970) PAGE NUMBERS BY ISSUE

January, 1-80
February, 81-144
March, 145-208
April, 209-288
May, 289-352
Supplement 1, 353-408
June, 409-474
July, 475-538
August, 539-602
September, 603-682
October, 683-746
Supplement 2, 747-830
November, 831-894
December, 895-958

and hypothalamic lesions, *346
and diabetes screening, 196-199
and diabetic retinopathy, 502-516
and glucose
and diabetes, *345-346
and glucose intolerance, *284
and glucose metabolism
in fasted normal dogs, 487-491
and infants of diabetic mothers, *950
and insulin, *283-284
and insulin secretion, 107
and insulin utilization, *593
and insulin-treated diabetics, *472
and islet cell carcinoma, *134
-like activity
in hypophysectomized rats, *737
and lipoatrophic diabetes, *285
during pregnancy, *598
release
and adrenergic blocking agents, *738
and amino acids, 113
and arginine monochloride and normal saline, *887-888
and hypothyroidism and thyrotoxicosis in children, *72
during sleep, *73
response to glucose
in obese children, *138
response to hypoglycemia, 23-27
and cholinergic blockade, *133
and starvation, *738
and thyrotoxicosis, *472
responses
in obese adolescents, 492-495
secretion
and 2-deoxy-D-glucose, 454-455
and fasting, 692
and hypophysectomy, 505-509
and idiopathic precocious puberty, *347
and pituitary stalk section, *591
and renal failure, *888-889
secretion and metabolism
in children with glucocorticoid-induced growth retardation, *673
in untreated diabetic children, *890

GUANIDINE
and insulin secretion, *734-735

GUINEA PIG
and phenformin inhibition of hepatic gluconeogenesis, 45
and steroid diabetes
and islet cells, 145-154

H

HAMMAN'S SIGN, *201

HAMSTERS, *See also* Golden hamsters
and tolbutamide study, 603-608

HB_{119}. *See* Glibenclamide

HEART
of alloxan diabetic rats, 326-327
aorta
mucopolysaccharides and diabetes, 639-643
and Candida meningitis, 441
function
and ethanol, *596
UGDP examinations of, 755-756

HEART DISEASE
angina pectoris
and sugar consumption, 923
in UGDP study, 764, 770, 783, 799, 800, 802, 803, 810
arteriosclerotic
in aged diabetics, *139
coronary
control of biochemical precursors of, *597-598
and sucrose intake, *73
and sugar, 923, 929
and diabetes study, *203
and glucose ingestion study, *201
and hemochromatosis, *285
ischemic
and diabetes incidence in Israel, 938-943
and insulin, *205
and scleredema, *735
in UGDP study, 765-766, 790-792

HEAT STROKE
and hyperglycemia and aketotic hyperosmolar acidosis, *531

HEMORRHAGE
capillary
and hyperlipoproteinemia, *886
and diabetic glaucoma, 944-947
ocular, *202

HEPARIN
and insulin secretion, *950
and lipemia retinalis, *670
and lipoprotein lipase activity in marasmus, *672
in skin of alloxan diabetic rats, 732

HEPARITIN SULFATE
in diabetic kidney tissue, 169

HEPATOMEGALY
and diabetic acidosis, *888
in Indian diabetics, *534

HEREDITY. *See also* Genes
and children of two diabetic parents, *532
and coexistent diabetes insipidus and mellitus, *949
and diabetes, 666
and age correction method, *530
and Klinefelter's syndrome, *597
and race, *532
and diabetic neuropathy, *529
and hyperzincuria, 240-246
and intraocular pressure response to topical corticosteroids, 715
and orotic aciduria, *592

HEXOKINASE
synthesis
and insulin, *735-736

HEXOSAMINE
in diabetic kidney tissue, 163-169

HISTIDINE
and food intake, *531
and insulin secretion, 109-114, 477

L-HISTIDINE
and insulin secretion, 102-107

HODGKIN'S DISEASE
and plasma copper, 234

HORMONES
enteric
and insulin secretion, *886
and free fatty acid mobilization and ketosis in fasting pregnant rats, 570
lipolytic
responsiveness to, *205
and McCune-Albright syndrome, *886
pancreatic
and maturity-onset diabetes, *285
polypeptide and protein
and lipid monolayers, *595-596
-producing tumors
in partially pancreatectomized rats, *884
and regulation of polyol pathway in aorta, *593
and ribose-induced hypoglycemia, 23-27

DIABETES: VOLUME 19 (1970) PAGE NUMBERS BY ISSUE

January, 1-80
February, 81-144
March, 145-208
April, 209-288
May, 289-352
Supplement 1, 353-408
June, 409-474
July, 475-538
August, 539-602
September, 603-682
October, 683-746
Supplement 2, 747-830
November, 831-894
December, 895-958

sex
and glucose tolerance, 430-432
and insulinemia, *133
and urinary cyclic AMP and cyclic GMP excretion, *530

HUNTER'S SYNDROME, *596

HURLER SYNDROME, *596

HYDROCHLOROTHIAZIDE
and diabetes insipidus, *528

HYDROCORTISONE
and glycogen synthesis, 919-920

N_1-p-HYDROXY-B-PHENETHYL-BIGUANIDE, 45

β-HYDROXYBUTYRATE
antilipolytic effects, *595
metabolism in rat brain, *202

17-HYDROXYCORTICOID
and carbohydrate intolerance in pheochromocytoma, *344

5-HYDROXYINDOLE ACETIC ACID
and insulin release, 478

HYDROXYPROLINE
incorporation
and insulin, 465-466

L-5 HYDROXYTRYPROPHAN
and insulin secretion, 478

5-HYDROXYTRYPTAMINE, *See* Serotonin

HYPERAMINOCIDEMIA
and pancreas glucagon secretion, 627

HYPERCHOLESTEROLEMIA
and heart disease, *598
treatment, *595

HYPERCHYLOMICRONEMIA
and lipemia retinalis, *670

HYPERGLYCEMIA
anacidotic
and focal seizures, *594
and L-asparaginase, *596
and "brittle" diabetes, *592
and cerebral edema, *204
and cortisone, 145
and diabetic coma, *348
and diazoxide, 271
and diazoxide analog, 630-638
diazoxide-induced, 228-232
fasting
in normals and diabetics, 571-577
and glucose metabolism in goosefish islet, 554-557
and glybenclamide, *282
and heat stroke, *531
and hyperosmolarity
in brittle diabetic with thyrotoxicosis, 70-71
and hypothalamic lesions, *346
and infection, 883
and insulin immunization, *672
and insulin release study, 429-436
and mannoheptulose, *347
and obesity
and insulin resistance, *670
and Regular insulin in massive doses, 28-32
and transient neonatal diabetes, *885
and unstable diabetes, 644-655

HYPERINSULINEMIA
and Cockayne's syndrome, *595
and Cushing's syndrome, *471
and diazoxide, 271
and hypothalamic lesions, *346
and glucagon, 432-436
and liver cirrhosis, *592
and myotonic dystrophy, *134
in nondiabetic children, *529
and proinsulin, *596
and tolbutamide, 607

HYPERKALEMIA
and amiloride, *887

HYPERKERATOSIS
of skin at insulin injection site, *202

HYPERKETONEMIA
and insulin secretion, *953

HYPERLIPEMIA
and malignancy, *953

HYPERLIPIDEMIA
and diabetes, *951
and heart disease, *597-598
and pancreatitis, *591

HYPERLIPOPROTEINEMIA
and Cockayne's syndrome, *595
and nailfold capillary study, *886

HYPEROSMOLARITY
in brittle diabetic with thyrotoxicosis, 70-71
and diabetic coma, *283, *348
and "transient" diabetes, *595

HYPERTENSION
and diazoxide treatment
and acute diabetic ketoacidosis, *73
ocular, *202
in UGDP study, 770, 783, 798, 799, 810
as cardiovascular disease risk factor, 764
chi-square tests of distribution of, 800
and mortality, 802, 803
and urine insulin, *472

HYPERTHYROIDISM
and pernicious anemia, 721

HYPERTRIGLYCERIDEMIA
and nailfold capillary study, *886
and oral contraceptives, *346
and serum immunoreactive insulin, *348

HYPERZINCURIA
and diabetes, 240-246

HYPOCALCEMIA
and glucagon, *206
and 2-thiophenecarboxylic acid, *596

HYPOCHONDRIASIS
and diabetes, 259-263

HYPOGLYCEMIA
and beta cell function, 607
and chlorpropamide, *885, *949, *953
chlorpropamide-induced, *672, 930-936
conditioned, *738
and diazoxide analog, 630-638
and epinephrine release, 688
and erythroblastosis fetalis, *470
factitious, *593-594
and glybenclamide, 264-270, 581-582
growth hormone response to and starvation, *738
and hepatocellular carcinoma, *348
and hypothalamic lesions, *346
and hypothermia, *205-206
and insulin
and "brittle" diabetes, *592
insulin-induced
and growth hormone and placental lactogen levels during pregnancy, *598
and growth hormone response in thyrotoxicosis, *472
and hypophysectomy, 506-507
ketotic
and gluconeogenesis and insulin, *205
and ketone infusion, *673

DIABETES: VOLUME 19 (1970) PAGE NUMBERS BY ISSUE

January, 1-80
February, 81-144
March, 145-208
April, 209-288
May, 289-352
Supplement 1, 353-408
June, 409-474
July, 475-538
August, 539-602
September, 603-682
October, 683-746
Supplement 2, 747-830
November, 831-894
December, 895-958

and mesenchymatous tumors, *349
and nonpancreatic tumors, 248-257
and oxytetracycline administration, 307
and phenformin, 45-48
and d-ribose, 11-16
and hormonal changes, 23-27
and salt bush, *468
and starvation, 688
in subclinical diabetes, 9
and streptozotocin, 86-87
and THAM, 559-562
and tolbutamide response in healthy subjects, *469
in UGDP study
and mortality, 806-807
and unstable diabetes, 644-655

HYPOINSULINISM
and pancreatitis, *888

HYPOKALEMIA
and diabetic coma, *283

HYPOLIPIDEMIA
in pancreatic diabetes, *736

HYPOLIPIDEMIC AGENTS, *736

HYPOPHYSEAL
infarction
and diabetes, *534

HYPOPHYSECTOMY
and hypothalamic lesions
and pancreatic islet changes, *886
intracranial, *671
and liver free fatty acid uptake and ketone body production, 924-928
and retinopathy, *345
and Spirometra mansonoides spargana implantation in rats, *737
transethmoido-sphenoidal, 509-510
and urinary cyclic AMP and cyclic GMP excretion, *530

HYPOTHALAMUS
and insulin, *594
lesions, *671
and plasma insulin and triglyceride, *346

HYPOTHERMIA
and hypoglycemia, *205-206

HYPOTHYROIDISM
and growth hormone release, *72
and insulin response to glucose and glucagon, *468-469
and pernicious anemia, 721

HYPOXIA
and insulin levels, *592

I

IMMUNOPURIFICATION
in glucagon-like immunoreactivity study, 615-616

INFANTS
anencephalic
insulin, blood sugar, and growth hormone levels, *885-886
of diabetic mothers, *139, *594-595
and congenital abnormalities, *953
glucose infusion study in, *203
glucose tolerance, insulin and growth hormone levels, *950
pancreatic insulin content in, 612
with erythroblastosis fetalis
and serum insulin, *470
glucose tolerance tests
and capillary blood sugar values, 176-181
and maple syrup urine disease, *284
newborn
and urine galactose, 529
and orotic aciduria
and uridine therapy, *592
premature
insulin secretion study in, 837-840
and transient diabetes, *885
and hyperosmolality, *595

INFECTION
in aged diabetics, *139
and amputation, 189-195
Candida meningitis in juvenile diabetics, 438-441, 443-444
and diabetic coma, *283
erythrasma
and diabetes, *348
mucormycosis
and diabetes, 881-883
and oxytetracycline, 310
and serum copper, 234

INSULIN
A-chain
urinary excretion by normal and diabetic subjects, 98-101
A and B chains
immunological studies, 409-417
action
in chickens, *886-887
and growth hormone, *593
action and secretion
in fasted mice, *885
and adenyl cyclase activity in fat cells, *673
and alanine C-14 and leucine C-14 incorporation into protein of E. coli, *672
and alloxan diabetes
and kidney damage, 35, 40
and amino acid metabolism, 727-728
in anencephalic infant, *885-886
antilipolytic effect of, 91-97
antisera
and proinsulin and C-peptides, 546-552
assays
of islet tissue, *594
and atherosclerosis, *205
biosynthesis, *469
and proinsulin, 539-545
"bound"
and glucose metabolism of brown fat cells, *887
and carbohydrate metabolism
in fetal rhesus monkey muscle, *344
and collagen synthesis by newborn rat bone, 465-466
and cortisol, *471
cutaneous reaction to, *201-202
deficiency
and growth hormone secretion, 519-523
and dialysis in diabetics, *345
displacement from blood capillaries, *472
dosage
and hyperglycemia and hypoglycemia in rabbits, 28-32
and hypoinsulinemia, 9
and retinopathy, *884
in UGDP study, 748-749, 768, 773, 789
double antibody assay, 127-131
and exercise and glucose turnover in dogs, *138
and factitious hypoglycemia, *593-594
fasting immunoreactive
and obesity, 494-495
and free fatty acid mobilization and ketosis
and pregnancy, 563-570
and growth hormone secretion, *472
and hexokinase synthesis, *735-736
hormonal and immunological properties, *206
human crystalline
from nondiabetic and diabetic patients, *344

DIABETES: VOLUME 19 (1970) PAGE NUMBERS BY ISSUE

January, 1-80
February, 81-144
March, 145-208
April, 209-288
May, 289-352
Supplement 1, 353-408
June, 409-474
July, 475-538
August, 539-602
September, 603-682
October, 683-746
Supplement 2, 747-830
November, 831-894
December, 895-958

hypoglycemia
and growth hormone response, *133
and hypothalamic satiety center, *594
immunization
and diabetes in rabbits, *672
immunoassayable
and glibenclamide, *282
immunoassays, *203
and proinsulin, *596
in rat islets, *203-204
immunoreactive
in bile, *469
in juvenile diabetics, *139
in portal and peripheral vein, 302-306
infusion
in growth hormone and glucose study in diabetics, *345-346
isolation from single human pancreas, 831-836
and ketoacidosis, *344
levels
and hypoxia, 592
-like activity
by perfused rat liver, 296-301
-like effects
of secretin and cholecystokinin-pancreozymin, *951
and lipemia retinalis, *670
and lipolysis, *593
and synalbumin, *670
and liver glycogen synthetase, *672
localization in beta cells, *887
and monomolecular films of mono-octadecyl phosphate and stearic acid, *595-596
peptide chains, *285
pig
antigenicity, *469-470
plasma amino acid response to, *348
porcine
and lipolysis and glucose oxidation in rat adipocytes, 209-216
and posthypoglycemic hyperglycemia and "brittle" diabetes, *592
and proinsulin, 289, 294-295
proinsulin conversion to, *889
radioimmunoassay, 127-131
in plasma and urine of obese and diabetic subjects, *135
response to arginine in growth hormone deficient children, *139
and streptozotocin, 88
Regular
hyperglycemic response to massive doses of, 28-32
release, 22
and adrenergic blocking agents, *738
and caffeine, *593
conditioned, *738
and diazoxide, *948
and epinephrine, *136
epinephrine and serotonin inhibition of, 480-485
and fructose, *953
gastrointestinal stimulus to, *950
and glibenclamide, *137-138
induced, 559-562
by insulinoma tissue, *952
and mannoheptulose, *347
and pancreatic glucagon, 429-436
from perfused rat pancreas, *345
and pheochromocytoma, *344
and ribose-induced hypoglycemia, 23-27
and serotonin, 475-478
and tolbutamide, 603-608
and xylitol, *737
requirement
and hypophysectomy, 505
resistance
and liver disease, *201
and obesity, *670
and transplantation of pancreatic insulinoma, 182-185
-resistant diabetes
spontaneous disappearance of, *884
and respiratory in liver mitochondria, *531
response
fetal, *534
and glucose intolerance, *284
and myotonia dystrophica, *471
and nonpancreatic tumors, 251
and obese adolescents, 492-500
in pancreatectomized dogs treated with oxytetracycline, 307-310
and pheochromocytoma, *598
and Sotos' syndrome, *72
response to glucose
and atherosclerosis, *138
in myotonic dystrophy patients, *134
secretion
and acromegaly, *951
and adrenergic receptors, *201
adrenergic regulation of, 688-692
and alpha adrenergic blockade, *949
and amino acids, *136
and amino acids and glucose, 109-114
and amino acid infusion, 217-227
biologic model of, 895-904
and C-terminal tetrapeptide amide of gastrin, *135, *597
and calcium-magnesium antagonism, *528
and 2-deoxy-D-glucose, 453-457
and diabetes, *73
and diazoxide analog, 630-638
and diazoxide and A025, 271-280
and diphenylhydantoin, *952
and enteric hormones, *886
and free fatty acids, *950
and gastrin, *135
and glucagon, 420-428
and glucose, *133
and guanidinoacetic acid, *734-735
and hyperketonemia, *953
in hypoglycemic children, *205
inhibition of, *284
and islet cell adenoma, *348
and pancreas blood flow, *596-597
and pituitary stalk section, *591
and potassium, *134
and race, *532
and remittent diabetes, 116-121
and subclinical diabetes, 1-9
and synergistic effect of amino acid pairs, 102-107
and theophylline and glucagon, 837-840
xylitol-induced, *135-136
secretion and resistance
and growth hormone, 488-491
sensitivity
and starvation, *738
-stimulated glucose uptake
and adipose tissue cells, *887
and streptozotocin diabetes, 90
synthesis, 91
tolerance tests
and arginine tolerance tests, *531-532
tyrosyl residues, *673
in UGDP study, 817-818
and mortality, 790-792
tolbutamide compared with, 809
and unstable diabetes, 645
urine, *472
and zinc, *949
and hyperzincuria, 243

INSULINEMIA
and sex hormones, *133

INSULINOMA
and blood sugar, serum insulin and free fatty acid interrelationships, 122-126

DIABETES: VOLUME 19 (1970) PAGE NUMBERS BY ISSUE

January, 1-80
February, 81-144
March, 145-208
April, 209-288
May, 289-352
Supplement 1, 353-408
June, 409-474
July, 475-538
August, 539-602
September, 603-682
October, 683-746
Supplement 2, 747-830
November, 831-894
December, 895-958

in childhood, *204

INTERMITTENT CLAUDICATION
in UGDP study, 767, 771, 783

INTRAOCULAR PRESSURE
response to topical corticosteroids, 715-718
in UGDP study, 755

IODINATION
in insulin radioimmunoassays, 410

IODOACETAMIDE
and lipolysis, *670

IRON
recommended dietary allowances of, 419

ISLETS OF LANGERHANS
and alloxan diabetes, 311
cholinergic and adrenergic nerve endings in, 691-692
in experimental immune diabetes, *672
and glibenclamide, *136
glucose oxidation
and hyperglycemia, tolbutamide and glucagon, 554-557
insulin release study, 559-562
microscopic studies in alloxan diabetic rats, 332-334

ISOELECTRIC FOCUSING, 832, 833

4,4'-ISOPROPYLIDENEDITHIO BIS 2,6-DI-T-BUTYLPHENOL
and serum lipids and lipoproteins, *595

ISRAEL
diabetes and ischemic heart disease survey in, 938-943
juvenile diabetes survey in, 585-590

K

KETOACIDOSIS, *283
clinical review, *592
and diabetes, *951
and diazoxide treatment for hypertension, *73
and emphysema and vomiting, *201
and plasma amino acid levels, 727-728
remittent diabetes following, 118-121
treatment, *344
in UGDP study, 769

KETONE BODIES
and fasting and hypophysectomy, 924-928
infusion in ketotic hypoglycemic children, *673

KETONURIA
in juvenile diabetes, 133
and plasma insulin, *135

KETOSIS
and growth hormone
and insulin resistance, 519-523
and hyperzincuria, 243
and insulin
and pregnancy and fasting, 563-570
and ketone infusion, *673
and serum glutamic-oxaloacetic transminase, 730-731
and stress, 692
in UGDP study, 750

KETOSTIX, 755

KIDNEY
acid mucopolysaccharide composition
and diabetes, 161-169
and alloxan, 685
and alloxan diabetes, 33-43, 315, 331
basement membrane
and diabetes, *949
cortical slices
glucose and ammonia production in, *952
and cyclamate ingestion, 623
and diabetes insipidus, *528
diabetic
glycoprotein changes in, 171-175
and diabetogenic effect of diazoxide, *73
and dialysis in diabetics, *345
disease
and Cockayne's syndrome, *595
and urine insulin, *472
and xylitol metabolism, *737
examination in UGDP study, 756
function
and growth hormone levels, 513-514, *888-889
and hypophysectomy with growth hormone administration, 509
glomerulus
sialoprotein in, *471
gluconeogenesis
in alloxan diabetic and acidotic starved animals, *135
and ammonia production in dogs, *735
and ammonia production in rat, *735
Goldblatt
after removal of pheochromocytoma, *344
nephrotic syndrome
and plasma lipoprotein lipase, *530
papillary necrosis, *470
perinephric abscess
and diabetes, *953

KIMMELSTIEL-WILSON SYNDROME, 168, 171

KLINEFELTER'S SYNDROME
and diabetes
and chromosome constitution, *597

KREBS CYCLE
and glucose metabolism, 554-557

KUNITZ PANCREATIC TRYPSIN INHIBITOR, 91-97
and lipolysis, 209-216

L

LACTATE
and ammonia production, *735
metabolism
and nonpancreatic tumors, 251-252
turnover
obesity, phenformin and, 64-68
obesity, starvation and, 53-62

LACTIC DEHYDROGENASE
and alloxan diabetes, 317-318

LACTOSE PLACEBO
in UGDP study, 749, 751, 768, 789

LANGERHANS, PAUL, *671

LESIONS
conjunctival vascular, *950
and diabetic diarrhea, *206
glomerular
and acid mucopolysaccharide changes in diabetic kidneys, 168-169
hypothalamic
in hypophysectomized rats, *886
and plasma insulin and triglyceride levels, *346
pancreatic
and glucagon secretion, *200
renal
in alloxan diabetic rats, 33-43

DIABETES: VOLUME 19 (1970) PAGE NUMBERS BY ISSUE

January, 1-80
February, 81-144
March, 145-208
April, 209-288
May, 289-352
Supplement 1, 353-408
June, 409-474
July, 475-538
August, 539-602
September, 603-682
October, 683-746
Supplement 2, 747-830
November, 831-894
December, 895-958

LEUCINE
and insulin secretion, 109-114, *136, 477
sensitivity
and islet cell tumors, *134
tolerance tests
and nonpancreatic tumors, 250

LEUCINE C-14
incorporation into protein of E. Coli and insulin, *672

L-LEUCINE
and insulin secretion, 102-107

LEUKEMIA
and hyperlipemia, *953
and L-asparaginase therapy, *596

LIGHT COAGULATION
and diabetic retinopathy, *472

LIKELIHOOD APPROACH
and statistical tests of UGDP study results, 794-796

LIPEMIA
and acute pancreatitis, *591
treatment, *595

LIPEMIA RETINALIS
and insulin, *670

LIPIDS
and hypolipidemic drugs, *736
and insulin and parathyroid hormone, *595-596
mobilization
and starvation, *885

LIPOATROPHIC DIABETES
and serum insulin and growth hormone, *285

LIPODYSTROPHY, *202
and fat cell function and insulin secretion, *285

LIPOLYSIS
in adipose tissues of pregnant rats, 570
and antilipolytic agents, *592-593
and β-hydroxybutyrate, *595
inhibition
and proinsulin, 290-295
by sulfhydryl reagents, *670
and insulin and proinsulin, 209-216
and ketone infusion, *673
and obesity, *283
and pituitary lipolytic peptides, *737
and porcine proinsulin, 91-97
rat adipose tissue
and lactic acid, *133
and synalbumin, *670

LIPOPROTEIN
synthesis
and glucose feeding, *530
and synthetic porcine secretin, *205

LIPOPROTEIN LIPASE
and diabetic lipemia, *591
in marasmus, *672
and nephrotic syndrome, *530

LIVER
and alloxan, 685
and alloxan diabetes in rats, 311, 331
amino acid uptake
and insulin, 728
bromsulphalein storage and transport
and diabetes and alcoholism, *531
carcinoma, *348
cholesterol and fatty acid synthesis
and chromium, 115
cirrhosis, *949-950
and diabetes, *671
and glucose intolerance and insulin resistance, *201
and glucose tolerance, free fatty acid and serum insulin responses, *592
and serum glucose, insulin, and growth hormone, *349
disease
and glucose intolerance and insulin resistance, *201
free fatty acid uptake and ketone body production
and fasting and hypophysectomy, 924-928
function
and diabetic acidosis, *888
gluconeogenesis
in alloxan diabetic and acidotic starved animals, *135
and phenformin, 45
and glucose disposal, *530
and glucose intolerance after starvation, 692
glucose release
and growth hormone, 489
glycogen
and diazoxide analog, 631, 633
and exercise, *888
of growth hormone-treated dog, 490-491
and threonine deficiency, *533
glycogen diseases
screening method for, *202
glycogen synthetase
and insulin, *672
in starved alloxan diabetic rats, 916-922
glycogenolysis
and serotonin, 477
homogenates and alloxan, 84
ketogenesis
and fasting and pregnancy, 564-569
lipids
in alloxan diabetic rats with and without arteriosclerosis, 318-319
metabolism
and glucose and ethanol, *470
mitochondria
and diabetes, *592
respiratory activities of, *531
perfused rat
insulin studies, 415-417
nonimmunoassayable insulin-like material produced by, 296-301
and phenformin, 45
phosphorylase
and glucagon, *349
rat
mitochondria, *202
structure and function
in Indian diabetics, *534
and untreated juvenile diabetes, *345
and Wolman's disease, *886

LYSIN-8-VASOPRESSIN, *949

LYSINE
and insulin release, 477

L-LYSINE
and insulin secretion, 102-107

M

MAGNESIUM
-calcium antagonism
and insulin secretion, *528
excretion during glucose and mercaptomerin diuresis, *672
in muscle of malnourished children, *734

MALNUTRITION
and body potassium, muscle electrolytes, and glycogen, *734
marasmus, *672
and myelination, 486

DIABETES: VOLUME 19 (1970) PAGE NUMBERS BY ISSUE

January, 1-80
February, 81-144
March, 145-208
April, 209-288
May, 289-352
Supplement 1, 353-408
June, 409-474
July, 475-538
August, 539-602
September, 603-682
October, 683-746
Supplement 2, 747-830
November, 831-894
December, 895-958

MANNOHEPTULOSE
and hyperglycemic-obese mice, *347
and insulin secretion studies, 421, 425-428

MANNOSE
metabolism
and cortisol, *284
and transfer of sodium ions, *591

D-MANNOSE
serum insulin response to, 155-160

MAPLE SYRUP URINE DISEASE, *284

MARASMUS
and lipoprotein lipase activity, *672

McCUNE-ALBRIGHT SYNDROME, *886

MEDROXYPROGESTERONE
and idiopathic precocious puberty, *347

MELLARIL
and glucose tolerance, 186-188

MENINGITIS, *See* Candida meningitis

MENSTRUATION
and glucose tolerance, 430-432
and hypophyseal infarction, *534

MENTAL ILLNESS
and diabetes, 259-263
and factitious hypoglycemia, *594
and glucose tolerance during chlorpromazine therapy, 186-188

MERCAPTOETHANOL
and glucagon-like immunoreactivity, 619
and lipolysis inhibition, *670

MERCAPTOMERIN
diuresis
calcium and magnesium excretion during, *672

6-MERCAPTOPURINE
and growth, *533-534

METABOLISM
amino acid, *205
and insulin, 727-728
and atherosclerosis, *347-348
brown adipose tissue
and denervation, *890
and cortisol, *284
and diazoxide
and beta adrenergic receptors, 228-232
and epinephrine and propranolol response in obese adolescents, *204
and glibenclamide, *884
glucose
in diabetic rats, *284
and obesity, *204
in rat epididymal fat tissue, *472
glucose and fat
and di-isopropylammonium dichloroacetate and sodium dichloroacetate, *889
glucose and lactate
and nonpancreatic tumors, 251-252
glucose lactate and β-hydroxybutyrate in rat brain, *202
glucose, pyruvate and glucose-6-phosphate
and cortisol, *471
glycogen
and starvation and alloxan diabetes, 916-922
growth hormone
and glucocorticoid-induced growth retardation, *673
insulin, *206
lactate and glucose, 53-62
lipid
and chromium, 115
liver
and glucose and ethanol, *470
metformin, *528
and obesity in adolescents, 492-500
and pancreatectomy, 695-697
proinsulin, *885
serotonin, 475-478
and starvation during neonatal period, *885
xylitol
and renal disease, *737

METABOLITES
and inhibition of glucose oxidase paper tests, 337-343

METAPYRONE
and partially pancreatectomized rats, *884

METFORMIN
absorption, distribution and elimination, *528
and intestinal absorption, *469

METHIMAZOLE, 71

METHOTREXATE
and growth, *533-534

3-METHYL-D-GLUCOSE
intestinal absorption
and alloxan diabetes, 683-687

α-METHYL GLUCOSIDE
serum insulin response to, 155-160

METHYSERGIDE MALEATE
and serotonin inhibition of insulin release, 477, 483

MICROANGIOPATHY
and diabetes, *137, *736
and glycoprotein, 171
and nailfold capillary studies, *886

MICROSCOPY
of arteries of alloxan diabetic rats, 326-330
electron
and beta cell insulin secretion study, 895-904
of diabetic rat liver, *202
in liver cells of Wolman's disease patients, *886
of pancreas beta cells of diabetic guinea pigs, 146-154
in proinsulin study, 540-545
of islets of Langerhans of alloxan diabetic rats, 332-334
of kidney of alloxan diabetic rat, 331
light
of pancreatic beta cells, *887
of liver of alloxan diabetic rat, 330
of ovary of alloxan diabetic rat, 331
of pancreas tumors, *346
of rat pancreas, 319-320

MINERALS. *See under individual names.*

MINNESOTA MULTIPHASIC PERSONALITY INVENTORY
and long-standing diabetes, 259-263

MIRACLE FRUIT, 718

MJ 1999
and beta adrenergic blockade, *201

MONKEYS. *See also* Rhesus monkeys.
vagotomy and splanchnicotomy
and blood insulin and sugar, *887

MONO-OCTADECYL PHOSPHATE
and insulin, *595-596

DIABETES: VOLUME 19 (1970) PAGE NUMBERS BY ISSUE

January, 1-80
February, 81-144
March, 145-208
April, 209-288
May, 289-352
Supplement 1, 353-408
June, 409-474
July, 475-538
August, 539-602
September, 603-682
October, 683-746
Supplement 2, 747-830
November, 831-894
December, 895-958

MONOSACCHARIDES
and serum insulin levels in rabbits, 155-160

MONTE CARLO MONITORING
of UGDP study mortality results, 793-794, 795, 813, 819, 822

MORTALITY
of aged diabetics, *139
and alloxan diabetes, 311-322
and amputation of lower extremities, 189-190, 193-194
and anacidotic hyperglycemia and focal seizures, *594
and Candida meningitis and juvenile diabetes, 438-441, 443-444
and diabetes and heart disease, *203
and diabetic coma, *284
fetal
and diabetic pregnancy, *673, *884
and hemochromatosis, *285
and lactic acidosis, *670
and mucormycosis, 881
neonatal
and tolbutamide therapy, *594
and nonketotic coma, *344
in UGDP study
by cause of death, 790
procedures for reporting and classifying, 775, 789-790

MOUSE
hyperglycemic and obese
and mannoheptulose, *347
insulin secretion and action and fasting in, *885
obesity and insulin resistance in, *670
parabiosis and diabetes in, *671

MUCOPOLYSACCHARIDES
aortic
and diabetes, 639-643
sulfate-35 uptake and incorporation into, *593

MUCOPOLYSACCHARIDOSIS
and vitamin A therapy, *596

MUCORMYCOSIS
and gangrene, 881-883

MUSCLE
amino acid
and cerebral gigantism, *735
capillaries
in diabetics, *890
in nondiabetics, *890
electrolytes
in malnourished children, *734
esophageal
and diabetes, *738
glucose uptake
and phenformin, 45
glycogen
and exercise, *888
glycogen synthetase, *137
myotonic dystrophy
and plasma insulin response to glucose, *134
rat
glycogen phosphorylase in, *137

MYELINATION
and malnutrition, 486

MYOCARDIAL INFARCTION
in alloxan diabetic arteriosclerotic rats, 325
and prednisone-glucose tolerance and serum lipids, *347
and sucrose intake, *73
and tolbutamide therapy, 811

MYOCARDITIS
and sulfonylureas, 809-811

MYOTONIC DYSTROPHY
and plasma insulin response to glucose, *134, *471

MYXEDEMA
and insulin response to glucose and glucagon, *468-469

N

NAVAJO INDIANS
and diabetes, *532

NEOMYCIN
and serum cholesterol and triglycerides, *889

NERVOUS SYSTEM
autonomic
and insulin-glucose axis, 692

NEUROPATHY, DIABETIC
and bilateral foot-drop, *472
and carbamazepine therapy, *137
in elderly, *73
and esophagus, *738
and joints, *470
study in synalbumin positive and negative subjects, *529

NICOTINAMIDE
and streptozotocin diabetes, 90, *889-890

NOMOGRAMS
for body surface and insulin dosage, 773

NOREPINEPHRINE
and lipolysis
and insulin and proinsulin study, 209-216
and plasma free fatty acids and blood sugar, *202
response of denervated adipose tissue to, *890

NUTRITION
and amino acid imbalance, *531
and chromium, 115
and decreased glucose utilization, *533
imaginary food intake
and plasma insulin levels, *735

O

OBESITY
and alloxan diabetes, 313
and blood glucose levels
and cancer proneness, *593
in children
and growth hormone response to oral glucose, *138
and diabetes, *137
and vascular disease, *137
and erythrasma, *348
and glucose metabolism, *204
and heart disease, *598
and insulin resistance, *670
and lactate turnover and gluconeogenesis, 53-62
and phenformin, 64-68
and lipolysis, *283
and mannoheptulose, *347
and metabolic response to epinephrine and propranolol, *204
and plasma insulin A-chain response to glucose loading, *136
and plasma and urine insulin, *135
and scleredema, *735
and serum insulin response to glucose, 458-463

ORAL CONTRACEPTIVES
and glucose tolerance, 3, *133, *951
and plasma insulin responses, *889
and plasma and serum copper, 234-235

DIABETES: VOLUME 19 (1970) PAGE NUMBERS BY ISSUE

January, 1-80
February, 81-144
March, 145-208
April, 209-288
May, 289-352
Supplement 1, 353-408
June, 409-474
July, 475-538
August, 539-602
September, 603-682
October, 683-746
Supplement 2, 747-830
November, 831-894
December, 895-958

and plasma triglyceride levels, *346
and serum fucose, *889
and subclinical diabetes, 8

ORAL HYPOGLYCEMIC AGENTS. *See also* Sulfonylureas *and under individual names.*
and beta cell suppression, 603-608
and diabetes
and vascular complications. *See* UGDP study.
FDA statement on, viii-ix
and high carbohydrate diet, *137
and pancreas oxygen consumption, *533
symposium on, *282-283
and vascular disease. *See* UGDP study.

OROTIC ACIDURIA
and uridine therapy, *592

OSCILLOMETRIC EXAMINATIONS, 756

OVARY
of alloxan diabetic rats, 331

OXYGEN
consumption
and starvation, *885
deprivation
and circulating insulin levels, *592

OXYTETRACYCLINE
and insulin response in pancreatectomized dogs, 307-310

P

PANCREAS
allografted
exocrine and endocrine functions of, *346-347
and alloxan, 685
alpha cells
and insulin secretion, *284
of arteriosclerotic and nonarteriosclerotic alloxan diabetic rats, 319-320
beta cell tumors, *134
beta cells
and alloxan diabetes, 33, 84
and conditioned hypoglycemia, *738
and diabetes onset, *73
and glibenclamide, *283
and leucine action, *136
peroxidase-labeled antibody technic, *887
proinsulin in, 539-545
proinsulin release by, 295
response to glucose, 906-914
secretion study, 895-904
and streptozotocin diabetes and nicotinamide therapy, *889-890
and subdiabetes, *534
and sufonylureas, 583
blood flow
and insulin secretion, *596-597
and diazoxide, 228-232
disease
diagnosis methods, *890
endocrine tumors, *346
fetal
proinsulin content, *888
and streptozotocin-induced diabetes, 610-613
of fetal and newborn rats
and glucose and insulin secretion study, *133
glucagon
and glucagon-like immunoreactivity, 614-622, 624-629
and insulin release, 429-436
glucagon secretion
in diabetics and normals, *200
gluconeogenic hormone
and maturity-onset diabetes, *285
hormone
and diabetes, *349
insulin release
and serotonin, 475-478
insulin secretion
and amino acid infusion, 217-227
and diphenylhydantoin, *952
and liver, 300-301
peripheral vein insulin concentrations as index of, 302-306
and xylitol, 21
insulinoma
transplantation into insulin-resistant juvenile diabetic, 182-185
islet activity
and sulfonylureas, 603-608
islet cell adenoma
and insulin secretion, *348
islets
and cystic fibrosis, *348
and glibenclamide, *136
and glucose 6-phosphatase, *534
and hyperglycemia, tolbutamide and glucagon, 554-557
and hypoglycemic sulphonylureas, *533
in hypophysectomized rats bearing hypothalamic lesions, *886
induced insulin release, 559-562
insulin immunoassays, *203-204
insulin production in, *468
proinsulin, 539-545
and proinsulin synthesis and conversion to insulin, *889
and steroid diabetes in guinea pigs, 145-154
isolation of insulin from, 831-836
perfused rat
calcium-magnesium antagonism in insulin secretion by, *528
and diazoxide and AO25 effect on insulin secretion, 271-280
and glucagon and insulin secretion study, 420-428
of premature infants, 837-840
rat
and proinsulin release, *345

PANCREATECTOMY
and insulin response
in oxytetracycline-treated dogs, 307-310
partial
and aminoglutethimide and metapyrone therapy, *884
and testosterone treatment, *134
in rat
two-stage procedure, 694-697

PANCREATITIS
and diabetes
and serum lipid levels, *736
and diabetic lipemia, *591
and serum insulin levels, *888

PANCREOZYMIN
and insulin secretion, *886

PARABIOSIS
and normal and diabetic mice, *671

PARKINSON'S DISEASE
and L-dopa, 342

PENNSYLVANIA AMISH
and diabetes, *532

PENTOSE CYCLE
and glucose metabolism, 554-557

PEPTIDES
diabetogenic, *204
pituitary, *737

C-PEPTIDES
and proinsulin, 546-552

DIABETES: VOLUME 19 (1970) PAGE NUMBERS BY ISSUE

January, 1-80
February, 81-144
March, 145-208
April, 209-288
May, 289-352
Supplement 1, 353-408
June, 409-474
July, 475-538
August, 539-602
September, 603-682
October, 683-746
Supplement 2, 747-830
November, 831-894
December, 895-958

PEROXIDASE LABELING
antibody technic, *887
in proinsulin study, 540-545

PHENFORMIN
and acetohexamide, *134
and bile insulin, *469
and glucose metabolism, 45-48
and inhibition of glucose transport by rat intestine, 50-52
and lactate turnover and gluconeogenesis in obesity, 64-68
and lipolysis, *592-593
and nondiabetic humans, *349
in UGDP study, 749, 751, 768, 812

PHENTOLAMINE
and growth hormone, insulin, free fatty acids and glucose, *738
and insulin secretion, 688-692, *949
and serotonin inhibition of insulin release, 482-483

PHENYL-ETHYL-BIGUANIDE
and lactic acidosis, *670

L-PHENYLALANINE
and insulin secretion, 102-107
tolerance test
and plasma growth hormone changes, *593

1,2-PHENYLENEDIAMINE, 83-84

PHENYLKETONURIA
and plasma growth hormone changes after phenylalanine tolerance tests, *593

PHEOCHROMOCYTOMA, *344
and diabetes, 691

PHOSPHODIESTERASE
and antilipolytic agents, *593

PHOSPHOLIPIDS
of platelets
in diabetics, 698-702

PHOSPHORYLATION OXIDATION
in diabetic mitochondria, *592

PHOTOCOAGULATION, *202, *948-949

PHOTOSENSITIVITY
and cyclamates, 623

PIGS
fructose stimulated insulin release in, *953
starvation during neonatal period in, *885

PITUITARY GLAND
ablation, *671
insufficiency
and hypophysectomy, 504
lipolytic peptides, *737
stalk section
in breast cancer patients, *591

PLACEBO. *See also* Lactose placebo.
-treated group in UGDP study
and mortality, 790-792, 817, 818

PLACENTA
lactogen, *598
and sulfonamides, 607-608
and transient neonatal diabetes, *885

PLASMA
amino acid
and cerebral gigantism, *735
and diabetic ketoacidosis, 727-728
response to insulin, *348
cholesteryl esters
and corn oil, *948
free fatty acids
and catecholamines, *202
free fatty acids, acetoacetate, and triglycerides
in pancreatectomized rats, 695-697
glucagon and glucagon-like immunoreactivity, 624-629
glucose
in phenformin study, 46-48
turnover and oxidation, *204
and xylitol, glucose and tolbutamide infusions, 19-20
glucose and insulin
in streptozotocin study, 88
growth hormone
and Cockayne's syndrome, *595
and diabetic ketosis therapy, 519-523
and phenylalanine tolerance test, *593
and transsphenoidal hypophysectomy, 504-516
growth hormone, immunoreactive insulin and glucose
and arginine and saline infusion, *887-888
immunoreactive insulin
in obese adolescents, 495-496
insulin
and amino acids, 109-114
circadian variations, *530-531
and Cushing's syndrome, *471
and diabetes, *597
and diabetes and Klinefelter's syndrome, *597
and glucose uptake, 571-577
and glibenclamide therapy, 581-582, *884
and growth hormone, 490-491
and hydrochloric acid, *952
during imaginary food intake, *735
immunoreactive, *73
and insulinoma diagnosis, *204
in nondiabetic relatives of diabetics, 1-9
and nonpancreatic tumors, 251
in normal fetus, *737
in obese and diabetic subjects, *135
and oral contraceptives, *889
and stress and diet, *888
and xylitol, glucose or tolbutamide infusion, 17-22
insulin A-chain
in obesity and diabetes, *136
insulin and free fatty acids
and propranolol therapy, *468
insulin, glucose and nonesterified fatty acids
in chicken, *886-887
insulin and glucose responses
in normal subjects, 842-850
insulin and growth hormone
during ribose-induced hypoglycemia, 23-27
in untreated diabetic children, *890
insulin response
in pregnant rhesus monkeys, *888
to stimulation of secretin release, *72
to tolbutamide, *469
insulin tests, *203
insulin and triglyceride
and hypothalamic lesions, *346
lactate and glycerol
and diazoxide, 230
lipoprotein lipase
and idiopathic nephrotic syndrome, *530
triglycerides
and oral contraceptives, *346
response to carbohydrates, fats and caloric intake, *736
zinc and copper
and diabetes, 234-238

POLYDIPSIA
and alloxan diabetes, 325
and chlorpropamide, *949

DIABETES: VOLUME 19 (1970) PAGE NUMBERS BY ISSUE

January, 1-80
February, 81-144
March, 145-208
April, 209-288
May, 289-352
Supplement 1, 353-408
June, 409-474
July, 475-538
August, 539-602
September, 603-682
October, 683-746
Supplement 2, 747-830
November, 831-894
December, 895-958

POLYOL PATHWAY
in aorta
hormonal regulation of, *593

POLYPHAGIA
and alloxan diabetes, 325

POLYURIA
and alloxan diabetes, 325
and chlorpropamide, *949

PONDERAL INDEX
and cancer proneness, *593

POTASSIUM
and diabetes, *134
ion transport
and ethacrynic acid, *671
and ketoacidosis treatment, *344
in malnourished children, *734
-retaining diuretics
and hyperkalemia, *887

PREDIABETES
and glucose intolerance, *284
and insulin response, *532
and pancreas beta cells, *534
prognosis, 880
and serum insulin responses, *529
and sulfonylureas, 608

PREDNISOLONE
and steroid diabetes in guinea pig, 145-154

PREDNISONE
-glucose tolerance
and myocardial infarction, *347

PREGNANCY. *See also* Pregnancy, diabetic.
and free fatty acids and ketosis
and insulin, 563-570
and glucose administration, *534
in identical twin of diabetic, 879
and pituitary growth hormone and placental lactogen, *598
and plasma zinc levels, 234
in rhesus monkeys
and plasma insulin response and glucose tolerance, *888
and serum fucose levels, *889
and urine insulin, *472

PREGNANCY, DIABETIC, *673, *884
and fetus pancreatic insulin, 610-613
and glucose tolerance, insulin and growth hormone levels of infants, *950
and sulfonamide therapy, 607-608
and tolbutamide, *594-595

PROGESTERONE
and insulinemia, *133

PROINSULIN, 90
antibodies to, 539-545
in fetal pancreas, *888
immunological study
and C-peptides, 546-552
and insulin immunoassays, *596
and insulin radioimmunoassays, 410
and lipolysis and glucose oxidation, 209-216
metabolism study in forearm, *885
porcine
antilipolytic effect of, 91-97
and rat epididymal fat cells and fat pieces, 289-295
release
by insulinoma tissue, *952
from perfused rat pancreas, *345
secretion
and phentolamine, 692
synthesis
in isolated rat islets, *889

H-3 PROLINE
incorporation
and insulin, 465-466

PRONETHALOL
and adenylcyclase activity in fat cells, *673

PROPRANOLOL
and diazoxide hyperglycemia, 230
and glucose, insulin, free fatty acids and acetone bodies, *670
and insulin response to gastrin, *135
response in obese adolescents, *204
and serotonin inhibition of insulin release, 481-482
and sugar, insulin and free fatty acids, *468

PROSTAGLANDIN E_1
and adenylcyclase activity in fat cells, *673

PROTEIN MEAL TEST, 493

PROTEINS
and body composition, *597
of E. coli
alanine C-14 and leucine C-14 incorporation into, *672
and insulin secretion, 217
malnutrition
and lipoprotein lipase activity, *672
from miracle fruit, 718
and trypsin, 619-620

PROTEINURIA
and diabetes
and urine diabetogenic peptide, *204

PUBERTY, PRECOCIOUS
and growth hormone secretion and medroxyprogesterone, *347

PUROMYCIN
and insulin secretion, 277, 425-426

PYRIDINE NUCLEOTIDE
formation
and hyperglycemia, tolbutamide and glucagon, 554-557

PYRIMIDINE
synthesis
and orotic aciduria, *592

PYRUVATE
and cortisol, *471
and hexokinase synthesis, *735

R

RABBIT
bile insulin study in, *469
hyperglycemic response to massive doses of insulin in, 28-32
immune diabetes in, *672
interruption of arterial blood flow to pancreas in, 83
intestinal sugar and sodium transport, *72
isolated pancreatic islets
insulin production in, *469
monosaccharide infusion in, 155-160

RACE
and acid mucopolysaccharide changes in diabetic kidneys, 163
and glucose tolerance and insulin secretion, *532
of infants and children in capillary blood sugar study, 177
and juvenile diabetes, 587-590
of patients in UGDP study, 758, 777, 779, 809
and mortality, 802, 803
and pernicious anemia with diabetes, 719
and portal and peripheral vein immunoreactive insulin study, 303

RAT
and alloxan diabetes
and cortical sponge kidneys, 33-43

DIABETES: VOLUME 19 (1970) PAGE NUMBERS BY ISSUE

January, 1-80
February, 81-144
March, 145-208
April, 209-288
May, 289-352
Supplement 1, 353-408
June, 409-474
July, 475-538
August, 539-602
September, 603-682
October, 683-746
Supplement 2, 747-830
November, 831-894
December, 895-958

and glycogen synthesis and starvation, 916-922
histopathologic studies of, 324-335
intestinal absorption study in, 683-687
and skin acidic glycosaminoglycans, 732-733
alloxan diabetic and acidotic starved
in gluconeogenesis study, *135
amino acid imbalance in, *531
arterial blood flow to pancreas
and alloxan action in, 81-84
arteriosclerosis and alloxan diabetes in, 311-322
blood sugar control in, *951-952
brain metabolism
and diabetes in, *284
conditioned insulin release in, *738
cortisol-stimulated gluconeogenesis in, *672
decreased glucose utilization in, *533
diabetic
and aortic mucopolysaccharides, 639-643
and intestinal sugar and amino acid transport, *736-737
and sulfate-35 uptake and incorporation into aortic mucopolysaccharides, *593
and testosterone treatment, *134
diet and carcass composition study in, *597
fasted
and metabolic effects of diazoxide, 228-232
fetal and newborn pancreas
and glucose and insulin secretion study, *133
fetal pancreas transplantation to maternal host in, 906-914
gluconeogenesis and ammonia production in, *735
glucose assimilation study in, *529
glucose feeding and lipoprotein synthesis in, *530
glucose tolerance and oral contraceptives in, *951
hypophysectomized
and implantation of Spirometra masonoides spargana, *737
pancreatic islet study in, *886
hypothalamic lesions
and plasma insulin and triglyceride levels in, *346
insulinemia
and sex hormones, *133
intestinal glucose transport in, 50-52
liver
and glucose disposal, *530
liver mitochondria
and diabetes, *531
pancreatectomy in, 694-697
partially pancreatectomized
delay of diabetes in, *884
and phenformin studies, 45
pregnant
and effect of insulin on free fatty acid mobilization and ketosis, 563-570
propranolol study in, *670
streptozotocin diabetes in, 85, 90
and fetus pancreatic insulin content, 610-613
threonine-deficient, *533
urinary cyclic AMP and cyclic GMP excretion, *530

RECHROMATOGRAPHY, 615

REFLECTANCE METER, 724-726

RETINA
lipemia, *670

RETINOPATHY, DIABETIC
and blood sugar, *948
and hypophysectomy, *345
and insulin, *884
and photocoagulation, *948-949
and pituitary ablation, 703-714
and transsphenoidal hypophysectomy, 502-516
treatment, *202
by light coagulation, *472

RHESUS MONKEYS
epinephrine suppression of portal venous insulin in, *136
fetal muscle
insulin and carbohydrate metabolism study of, *344
glucose intolerance following head injury in, *596
plasma insulin response after xylitol, glucose or tolbutamide infusion in, 17-22
pregnant
plasma insulin response and glucose tolerance in, *888
streptozotocin study in, 85-90

RHEUMATOID ARTHRITIS
serum copper in, 234

D-RIBOSE
-induced hypoglycemia
hormonal changes during, 23-27
oral administration to diabetics, 11-16
serum insulin response to, 155-160

S

SACCHARIN
and photosensitivity to sunlight, 479, 501

SAND RAT
and diabetes
and diet, *468

SCLEREDEMA
and diabetes, *735, *884

SECRETIN
and insulin secretion, *886
insulin-like effects, *951
release
blood sugar and plasma insulin response to, *72
synthetic porcine
lipolytic activity, *205

SEROTONIN
and insulin release, 475-478, 480-485

SERUM
anti-insulin
in insulin assays, *594
calcium
and alloxan diabetes, 318
chlorpropamide
and chlorpropamide-induced hypoglycemia, 933-936
cholesterol
and alloxan diabetes, 317
and dietary chromium, 115
in UGDP study, 764, 765, 768, 769, 770, 782, 783, 810
cholesterol and triglycerides
and neomycin and clofibrate, *889
corticosterone
and alloxan diabetes, 318
creatinine
and UGDP study, 756, 764, 767, 768, 770, 782, 798, 800, 802, 803, 810
free fatty acids
and alloxan diabetes, 316
and oral ribose ingestion, 24
free fatty acids, insulin, glucagon, and growth hormone
in normals and juvenile diabetics, *470
fucose
and glucose loading, *887

DIABETES: VOLUME 19 (1970) PAGE NUMBERS BY ISSUE

January, 1-80
February, 81-144
March, 145-208
April, 209-288
May, 289-352
Supplement 1, 353-408
June, 409-474
July, 475-538
August, 539-602
September, 603-682
October, 683-746
Supplement 2, 747-830
November, 831-894
December, 895-958

in pregnancy and during oral contraceptive use, *889
glucose and amylase
and diagnosis of pancreatic disease, *890
glucose, insulin, free fatty acids and acetone bodies
and propranolol, *670
glucose, insulin, and growth hormone
and liver cirrhosis, *349
glucose response
to oral d-ribose, 11-16
glutamic-oxaloacetic transaminase, 730-731
and glibenclamide therapy, 582
growth hormone
and McCune-Albright syndrome, *886
growth hormone and insulin
in females without glucose intolerance, *529-530
insulin
and acromegaly, *283-284
blood sugar and free fatty acids during tolbutamide testing, 122-126
and chronic pancreatitis, *888
and cystic fibrosis, *348
and diabetes diagnosis, 865
and diazoxide analog, 633
and growth hormone, 196-199
in infants of diabetic mothers, *950
in infants with erythroblastosis fetalis, *470
in juvenile diabetes, *139
and liver cirrhosis, *592
and monosaccharides, 155-160
insulin and growth hormone, 196-199
and lipoatrophic diabetes, *285
insulin response, *139
to glucose in obesity and mild diabetes, 458-463
in identical twin of diabetic, 879
to oral d-ribose, 14-16
in prediabetes and diabetes, *529
lipids
and diabetes, 698-702, *736
and myocardial infarction, *347
in relatives of diabetics, *736, *952
in UGDP study, 757
lipids and lipoproteins
and DH-581, *595
in untreated diabetic children, *345
potassium
and glucose ingestion, *201
zinc
and diabetes, *532

SEX
and acid mucopolysaccharide changes in diabetic kidneys, 163
in diabetes prevalence study, 657
and glucose tolerance, *206, 430-432
and glucose tolerance tests, 849
and hyperzincuria, 243-244
of infants and children in capillary blood sugar study, 177
and juvenile diabetes, 589
of patients in UGDP study, 777, 779, 809
and blood glucose values, 762, 763
and blood pressure, 763, 767
and body weight, 763, 765, 773
and cardiothoracic ratios, 769
and cardiovascular risk factors, 770, 771
and mortality, 802, 803
and serum cholesterol levels, 769
and serum creatinine levels, 768
and visual acuity, 766
and pernicious anemia and diabetes, 719, 721
and personality patterns of diabetics, 259-263
and portal and peripheral vein immunoreactive insulin study, 303
and serum growth hormone and insulin levels, *529-530
and urinary insulin A-chain excretion, 99

SEX ORGANS
of alloxan diabetic rats, 326

SEXUAL ACTIVITIES
and alloxan diabetes and arteriosclerosis, 311-322
histopathologic studies, 324-335

SHOCK
in aged diabetics, *139

SKIN
acidic glycosaminoglycans
in alloxan diabetic rats, 732-733
and cyclamates, 623
erythrasma
and diabetes, *348
mucormycosis
and diabetes, 881-883
reactions to insulin injections, *201-202
scleredema
and diabetes, *735, *884
sensitivity to sunlight
and cyclamates, 479, 501

SLEEP
growth hormone release during, *73

SMOKING
and heart disease, *73
and sugar consumption, 923, 929

SODIUM
intestinal absorption of
in alloxan diabetic rats, 683-687

SODIUM DICHLOROACETATE, *889

SODIUM PUMPS
and hexose transfer and metabolism, *591

SOMOGYI-EFFECT, *592

SOMOGYI-NELSON TECHNIC, 110

SORBITOL
and hyperglycemia, *593

SOTALOL, 455

SOTOS' SYNDROME, *72

SOYBEAN TRYPSIN INHIBITOR, 91-97

SPIROMETRA MANSONOIDES SPARGANA
implantation in hypophysectomized rats, *737

SPLANCHNICOTOMY
and blood insulin and sugar, *887

SPLANCHNOMEGALY
etiology, *884

STARVATION
and alloxan, 685-686
and carbohydrate intolerance, *953
and glucose intolerance, *737-738
and glucose metabolism and growth hormone, 487-491
and glycogen synthesis
and alloxan diabetes, 916-922
and hypophysectomy
and liver function, 924-928
and insulin secretion
adrenergic regulation of, 688-692
and insulin secretion and action, *885
and ketosis
and pregnancy, 563-570
and lactate turnover and gluconeogenesis, 53-62
during neonatal period, *885

STEROIDS
-induced glaucoma, *202

DIABETES: VOLUME 19 (1970) PAGE NUMBERS BY ISSUE

January, 1-80
February, 81-144
March, 145-208
April, 209-288
May, 289-352
Supplement 1, 353-408
June, 409-474
July, 475-538
August, 539-602
September, 603-682
October, 683-746
Supplement 2, 747-830
November, 831-894
December, 895-958

STEVIOL, 841

STREPTOZOTOCIN
in chicken, *886-887
and conditioned hypoglycemia, *738
diabetogenic effects of, 85-90
-induced diabetes, 85-90
and beta cell damage and nicotinamide, *889-890
and fetus pancreatic insulin content, 610-613

STRESS
and beta adrenergic blockade, *201
and 2-deoxy-D-glucose, 454
and hypoinsulinemia, 9
and ketosis, 692
and plasma insulin and blood glucose, *888

SUCROSE
intake
and coronary heart disease, *73

SUGAR
and coronary heart disease, 923, 929
intestinal absorption of
in alloxan diabetic rats, 683-687
transfer
and sodium ion transfer, *591
transport
in diabetic rats, *736-737
in rabbit ileum, *72

SULFATE-35
incorporation into aortic glycosaminoglycans
and diabetes, 639-643
uptake and incorporation into aortic mucopolysaccharides
and diabetes, *593

SULFHYDRYL REAGENTS
and lipolysis, *670

SULFONYLUREAS
glibenclamide, 264-270, 579-584
and pancreas islet activity, 603-608
in UGDP study
ADA statment on, v
AMA Council on Drugs statement on, vii
FDA statment on, ix
literature review, 809, 811
tolbutamide as therapeutic agent in, 748

SULFUR
in insulin, 835

SURGERY
amputation
and gangrene, *138
lower extremity, 189-195
denervation of brown adipose tissue, *890
and diabetes, *598
and tolbutamide administration, *532-533
and hemorrhagic glaucoma, 946-947
hypophysectomy, *345
in rats bearing hypothalamic lesions, *886
for islet cell tumors, *134
ligation of pancreatico-duodenal arteries in rats, 81-84
pancreatectomy. *See* Pancreatectomy
pheochromocytoma removal, *344
pituitary ablation, *671
and diabetic retinopathy, 703-714
pituitary stalk section, *591
splanchnicotomy
and blood insulin and sugar, *887
transplantation of pancreatic insulinoma, 182-185
transsphenoidal hypophysectomy, 502-516
vagotomy
and blood insulin and sugar, *887

SYNALBUMIN
and lipolysis, *670
positive and negative subjects
diabetic neuropathy study in, *529

SYNERGISTIC EFFECT
of amino acid pairs upon insulin secretion, 102-107
of amino acids and glucose upon insulin secretion, 109-114

T

TADPOLES
hepatic glycogen synthetase and insulin in, *672

TEETH
extractions
and Candida meningitis, 443

TES-TAPE
inhibition by reducing metabolites, 337-343

TESTOSTERONE
and diabetes, *134
inhibition
and sweetening agents, 841
and insulinemia, *133

THAM
and insulin release, 559-562

THEOPHYLLINE
and dibutyryl cyclic AMP
in study of antilypolytic agents, *592
and insulin secretion
in premature infants, 837-840
and lipolysis
and insulin and proinsulin study, 209-216
and proinsulin, 290-294

THREONINE
deficiency
and blood glucose and liver glycogen, *533

THYROID. *See also* Hyperthyroidism; Hypothyroidism
discharge rate
and pituitary stalk section, *591
disease
and pernicious anemia, 722
lymphocytic infiltration of, 443

THYROTOXICOSIS
and brittle diabetes, 70-71
and growth hormone release, *72
and growth hormone response to insulin-induced hypoglycemia, *472
and insulin response to glucose and glucagon, *468-469

TISSUES
adipose
in fasting pregnant rats, 567-568
and insulin-stimulated glucose uptake, *887
response to lipolytic hormones, *205
and sulfhydryl inhibition of lipolysis, *670
brown adipose
and denervation, *890
brown fat cells
glucose metabolism and "bound insulin" in, *887
fat cells
adenyl cyclase activity in, *673
fetal pancreas
transplanted to maternal hosts, 906-914
insulinoma
and proinsulin and insulin release, *952

DIABETES: VOLUME 19 (1970) PAGE NUMBERS BY ISSUE

January, 1-80
February, 81-144
March, 145-208
April, 209-288
May, 289-352
Supplement 1, 353-408
June, 409-474
July, 475-538
August, 539-602
September, 603-682
October, 683-746
Supplement 2, 747-830
November, 831-894
December, 895-958

islet
insulin assays, *594
kidney
acid mucopolysaccharides, 161-169
muscle of fetal rhesus monkeys
and insulin and carbohydrate metabolism study, *344
normal and diabetic
and glucose and fat metabolism, *889
perfused rat pancreas
and diazoxide and A025 effect on insulin secretion, 271-280
rat adipose, *133
and lipolysis and glucose oxidation, 209-216
rat bone
and collagen synthesis and insulin, 465-466
rat brain
metabolism studies, *202
rat epididymal adipose
insulin effect on hexokinase synthesis in, *735-736
rat epididymal fat
effect of porcine proinsulin on, 289-295
glucose metabolism in, *472
rat heart
and ethanol, *596
rat islet
insulin immunoassays, *203-204
rat liver
and diabetes, *202
effects of fasting and hypophysectomy on, 924-928
nonimmunoassayable insulin-like activity in, 296-301

TOLBUTAMIDE
administration
during surgery, *598
animal studies, 809
and bile insulin, *469
and diabetic pregnancy, *594-595
and diazoxide analog, 633
and glucose metabolism
in goosefish islet, 554-557
insulin response to
and 2-deoxy-D-glucose, 453-457
and insulin response to glucose
in myotonic dystrophy patients, *134
and insulin secretion, *886
in fasted mice, *885
and mannoheptulose, 420-428
and lipolysis, *593
plasma insulin response to, 17-22
and blood glucose level, *469
and remittent diabetes, 118
response
in children of two diabetic parents, *532
during surgery
and diabetes control, *533
test
and glucose regulation, *950-951
in normal subjects and patients with insulinoma, 122-126
therapy, 467-468
FDA statement on, 467-468
tolerance tests
and islet cell tumors, *134
and nonpancreatic tumors, 250
and streptozotocin, 87
in UGDP study, 807, 810-812, 817, 818
compared with insulin, 809
dosage, 749, 768, 789
and mortality, 790-792

TOLBUTAMIDE SODIUM
and pancreas islet activity, 603-608

TRANSPLANTATION
of fetal rat pancreas to maternal host
and beta cell response to glucose, 906-914
of pancreas allografts
and exocrine and endocrine functions, *346-347
of pancreatic insulinoma into insulin-resistant juvenile diabetic, 182-185

TRIGLYCERIDE LIPASE
and antilipolytic agents, *593

TRIS HYDROXYMETHYL, *See* THAM

TRYPSIN
and fat cell glucose metabolism, *887
and glucagon-like immunoreactivity, 619-620

TRYPTIC DIGESTION
in insulin isolation study, 834
in glucagon-like immunoreactivity study, 616

L-TRYPTOPHAN
and insulin secretion, 477

TUMORS
beta cell
treatment, *134
Ehrlich ascites
glycolysis and ethacrynic acid, *671
hormone-producing
in partially pancreatectomized rats, *884
insulinoma
and diazoxide, *948
proinsulin and insulin release, *952
mesenchymatous
and hypoglycemia, *349
nonpancreatic
and hypoglycemia, 248-257
of pancreas, *346
pheochromocytoma, *344
and insulin release, *598
and Zellinger-Ellison syndrome, *284

TWINS
identical
and diabetes, 878-880

TYROSYL RESIDUES
location in insulin, *673

U

UBIQUINONE
in diabetic mitochondria, *592

UGDP STUDY OF HYPOGLYCEMIC AGENTS AND VASCULAR DISEASE
ADA statement on, iii-v
AMA Council on Drugs statement on, vi-vii
baseline clinical and laboratory findings, 770-771
bias reduction methods, 757
biothesiometry measurements in, 757
blood glucose values of patients in, 780, 781
by age and sex, 763, 764, 765
blood pressure variables in, 763
by age and sex, 767
body weight variables in, 762-763
percentage distribution of patients by age and sex and, 765
cardiothoracic ratio variables in, 764, 769, 782
cardiovascular risk factor variables in, 764-768
chronology, 747
compared with other studies, 809-812
conclusions, 812-814
demographic characteristics of patients in, 758-759, 774
diabetes diagnosis criteria in, 750, 769-770, 779, 789

DIABETES: VOLUME 19 (1970) PAGE NUMBERS BY ISSUE

January, 1-80
February, 81-144
March, 145-208
April, 209-288
May, 289-352
Supplement 1, 353-408
June, 409-474
July, 475-538
August, 539-602
September, 603-682
October, 683-746
Supplement 2, 747-830
November, 831-894
December, 895-958

diet, 749-750
distribution of patients in, 809, 810
by blood pressure, 782
by relative body weight, 781
by selected baseline characteristics, 783
by visual acuity measurements, 781
eye examinations in, 755
family history of patients in, 778
follow-up procedures, 803-804
FDA statement on, viii-ix
fundus photograph reading code for, 776
glucose tolerance tests in, 754-755, 759-762, 780
heart examination, 755-756
information obtained on patients in, 774-775
kidney examinations in, 756
life table analysis, 816
measures of adherence to assigned treatment, 804
monitoring of treatment effects, 753-754
mortality results, 790-792, 813, 817-818, 821-822
and accuracy of diabetes diagnosis, 797-798
and adherence to treatment, 804
by baseline characteristics, 802, 803
and blood glucose control, 804-806
and characteristics of deceased patients, 826-830
by clinic, 807-809, 825-826
and comparability of treatment groups, 798-803
and estimated probability of death, 816
and hypoglycemia, 806-807
Monte Carlo monitoring of, 819
multiple regression analysis of, 822-824
and probability of death model, 819-820
and simulation procedure, 820-821
statistical evaluation of, 792-796
tolbutamide-insulin comparisons, 809
and use of other drugs, 809
validity tests of, 797-809
objectives, 747, 768
organization of, 747-748
patient eligibility for, 768-769
patient examination schedule, 751-752
patient examinations, 754-755
patient recruitment for, 750, 789
peripheral vascular examination, 756-757
quality control methods, 752-753
race of patients in, 777
serum cholesterol variables in, 764, 768, 769, 782
serum creatinine variables in, 764, 767, 768, 782
serum lipid determinations in, 757
sex and age of patients at entry, 777
sex and race of patients in, 779
statement on tolbutamide usage, 467-468
therapeutic regimens, 768, 789
treatments, 748-751, 769
visual acuity variables in, 763
by age and sex, 766

ULCER
gastric
in male and female rats, 325

UNIVERSITY GROUP DIABETES PROGRAM. *See* UGDP study of hypoglycemic agents and vascular disease

UNOPETTE, 177

URACIL
and orotic aciduria, •592

UREMIA
and growth hormone levels, •888-889
and xylitol, •737

URIDINE
and hereditary orotic aciduria, •592

URINE
acetone, 755
catecholamines
and starvation, 688-692
diabetogenic peptide, •204
estrogen
and McCune-Albright syndrome, •886
excretion
in streptozotocin study, 87
galactose
in newborn infants, •529
glucosamine acetoacetate condensate, •531
glucose
in UGDP study, 755
glucose oxidase test
inhibition by reducing metabolites, 337-343
guanosine 3′,5′-monophosphate and cyclic adenosine 3′,5′-monophosphate excretion, •530
immunoasssayable insulin, •472
immunoassays, 98-101
insulin
in obese and diabetic subjects, •135
insulin A chain excretion by normal and diabetic subjects, 98-101
insulin tests, •203
metformin excretion, •528
orotic acid
and orotic aciduria, •592
sugar
and alloxan diabetes, 313
sugar excretion
and calorie requirements in diabetics, •673
sugar and insulin
and glibenclamide, 581
tests
in alloxan diabetic rats with and without arteriosclerosis, 318
of diabetics with Candida meningitis, 438-439
in UGDP study, 756
zinc
and diabetes, 240-246

V

VAGOTOMY
and blood insulin and sugar, •887

VASCULAR DISEASE. *See also* UGDP study
and diabetes
and obesity, •137
and personality patterns, 259-263
diagnosis
and biothesiometry measurements, 757
and hypoinsulinemia, 9
and insulin, •205

VASOPRESSIN
site of action of, •134

VEINS
insulin concentration
and epinephrine, 136
portal and peripheral
immunoreactive insulin concentrations in, 302-306

VINCRISTINE
and insulin secretion, 902

VISION
and hemorrhagic glaucoma, 946
of patients in UGDP study, 763, 770, 781, 798, 799, 810

DIABETES: VOLUME 19 (1970) PAGE NUMBERS BY ISSUE

January, 1-80
February, 81-144
March, 145-208
April, 209-288
May, 289-352
Supplement 1, 353-408
June, 409-474
July, 475-538
August, 539-602
September, 603-682
October, 683-746
Supplement 2, 747-830
November, 831-894
December, 895-958

by age and sex, 766
and mortality, 802, 803
VITAMINS
A
and mucopolysaccharidosis, *596
B_{12}
absorption after metformin therapy, *469
and pernicious anemia, 720, 721
VOMITING
and emphysema in diabetic coma, *201

W

WEIGHT. *See* Body weight; Obesity
WILSON'S DISEASE
plasma copper in, 234
WOLMAN'S DISEASE, *886

X

X RAYS
in UGDP study, 756, 764, 798-799
XYLITOL
-induced insulin secretion in dogs, *135-136
metabolism
and kidney disease, *737
plasma insulin response to, 17-22
D-XYLOSE
absorption after metformin therapy, *469
intestinal absorption in alloxan diabetic rats, 683-687
serum insulin response to, 155-160
XYZ SYNDROME
and diabetes and Klinefelter's syndrome, *597

Y

YTTRIUM-90
and pituitary ablation, *671

Z

ZAGREB, YUGOSLAVIA
diabetes survey in, *471
ZINC
and insulin release
and THAM, 562
insulin-binding, *949
ZOLLINGER-ELLISON SYNDROME, *284

DIABETES: VOLUME 19 (1970) PAGE NUMBERS BY ISSUE

January, 1-80
February, 81-144
March, 145-208
April, 209-288
May, 289-352
Supplement 1, 353-408
June, 409-474
July, 475-538
August, 539-602
September, 603-682
October, 683-746
Supplement 2, 747-830
November, 831-894
December, 895-958

AUTHOR INDEX 1970

In this index are the names of authors of articles that have appeared in DIABETES and those whose articles have been abstracted in the Journal during 1970. Entries marked with an asterisk (*) indicate authors of material that appeared in the ABSTRACTS only. The Subject Index appears on page 1.

A

Aarons, J. H., 524-526
Abraham, J. M., *72
Abraira, C., *735
Achkar, Edgar J., *285
Ackerman, Eugene, *345-346, 644-655
Adachi, M., *596
Adam, Peter A. J., *203
Adnitt, P. I., *948
Aguilar-Parada, E. *200
Aharonson, Z., *468
Aiello, L. M., *948-949
Aiyer, L., *137
Akerblom, Hans K., *133, *670
Alburn, H. E., *951
Albutt, E. C., *345, *948
Aliberti, Giuseppe, *468-469
Alippi, R. M., 732-733
Alley, R. A., *529-530
Alleyne, G. A. O., *734
Allison, S. P., *468
Alric, R., *136
Alsever, Robert N., *734-735
Altschuld, Ruth A., 50-52
Altszuler, Norman, 487-491
Anderson, W. Banks, Jr., *202
Andreani, Domenico, *468-469, *528
Andres, Reubin, 127-131
Antoniades, H. N., 296-301
Antony, G. J., *591
Appels, A., *347
Arbenz, U., *469
Ariyoshi, Yutaka, *284
Asher, R. R., *952
Asplund, K., *133
Aspray, D. W., *593
Assan, R., *283, *344
Aubert, Ph., *283, *344
Auzepy, Ph., *284
Azerad, E., *670

B

Babinet, J. P., *345
Bacon, G. E., *672
Bagdade, John D., *346, *591
Baghdassarian, Alice, *949
Baile, C. A., *951
Bailey, Richard E., 842-851, *948
Baker, Lester, *201
Balant, L., *345
Balart, Louis A., *738
Balodimos, Marios C., *345, *528-529, *670, *948-949, *950, *953
Banerji, N. K., *529
Bank, S., *736
Barcai, Avner, *201
Barnett, D. M., 944-947
Barnett, J., *737
Barrett, Richard, *206
Barron, Kevin D., *594
Barry, Kevin G., *344
Barry, R. J. C., *591
Barss, Margaret, *671
Basabe, Juan C., *133, *134, 271-280, 630-638
Bassler, K.H., *737
Bates, Robert W., *884
Baum, David, *592
Baumslag, Naomi, 664-669
Baxter, John D., *205-206
Beaconsfield, Peter, 23-27
Beatty, C. H., *344
Beaven, D., *889-890
Beck, Lyle V., 559-562
Becker, Bernard, 715-718
Becker, Kenneth L., *470, 610-613
Beckmann, Rüdger, *528
Becroft, David M.O., *592
Beetham, William P., *528, *948-949
Beigelman, Paul M., *201, *344, *592
Beisswenger, P. J., *949
Bejar, Raphael L., *735
Bemand, B. V., *468
Bengtsson, G., *885
Bennett, Leslie L., *528
Berchtold, P., *469
Berenson, Gerald S., 161-170, 171-175
Berger, S., 217-227
Bergman, Halvar, *283
Bergström, Jonas, *344
Beringer, A., *534
Berkowitz, Donald, *592
Bernard, Waldo, *884
Bernardis, Lee L., *346
Bernheim, R., *137
Bersohn, I., *737
Berson, Solomon A., 453-457
Bhatia, C. K., 579-584
Biener, Jeana, *670
Bierman, Edwin L., *346
Bilder, Joan H., 176-181, *950
Bilic, N., 81-84
Birk, Sharon A., *889
Bitensky, M. W., *593
Bjorntorp, Per, *283
Blackard, William G., *133, 302-306, *884
Blatt, Lois M., *672
Blizzard, Robert M., *531-532, *595, *887-888, *949
Bloom, M. E., *592
Blotner, Harry, *949
Bocek, R. M., *344
Boder, George B., *469
Bolinger, Robert T., *136
Bolli, P., *469
Bongiorno, M., *532
Bongiovanni, Alfred M., *673
Bonnet-Boutier, M., *137
Bonorris, George, 307-310
Booker, J., *952
Bookman, John J., *594-595
Bornstein, J., 465-466
Bortz, Walter M., *204
Boshell, Buris R., 53-63, 248-259, 863-868
Bottermann, P., *133
Boucher, Barbara, 23-27, *884
Boveris, A. A., *592
Bowser, E. Nelson, *206
Boyns, A. R., *469
Bozzini, C. E., 732-733
Bradford, Reagan H., *595
Bradley, R. F., *953
Brancato, Paul, *534
Brandt, Ira K., *593
Brasel, Jo Anne, *595
Bretz, Gedeon W., *949
Bricaire, H., *471
Brielmaier, Joan, *596
Briggaman, Robert A., *884
Brink, Andries J., *596
Brooks, John R., *134
Brooks, Marion H., *344
Brown, G. A., *890
Brown, Joseph D., 91-97, *592-593
Bruce, David H., *884
Brunfeldt, K., *344, *949
Buchanan, Keith D., *597, *598
Buhi, William C., *598, *889
Bulpitt, C. J., 703-714

DIABETES: VOLUME 19 (1970) PAGE NUMBERS BY ISSUE

January, 1-80
February, 81-144
March, 145-208
April, 209-288
May, 289-352
Supplement 1, 353-408
June, 409-474
July, 475-538
August, 539-602
September, 603-682
October, 683-746
Supplement 2, 747-830
November, 831-894
December, 895-958

Bunch, Leitha D., *532
Buncher, C. Ralph, *201
Burek, Lynne, *346
Burian, K., *534
Burnham, Clinton E., *136, 852-862
Burr, I. M., *345, *889-890
Buse, John, *949
Buse, Maria G., *949
Butler, E. J., *886-887

C

Cahill, Geeorge F., Jr., *135, *202, 727-729, *885
Calvert, Deane E., *670
Camerini-Davalos, Rafael, *950
Campbell, James, *593
Campbell, Robert G., *953
Canivet, J., *345, *671
Caplan, Joan, *672
Carroll, Kevin F., *736
Carter, J. R., *887
Cassano, Cataldo, *468-469
Cassar, J., 878-880
Castelli, William P., *670
Castells, Salvador, *593
Castleman, Benjamin, *949-950
Castro, Albert, 842-851, *948
Cattaneo de Peralta Ramos, M., *592
Cavalieri, R. R., *349
Cerasi, Erol, *201, *469
Challoner, David R., 289-295
Chamberlain, M. J., *468
Chance, G. W., *345, *890, *948
Chance, Ronald E., *469
Chazan, Bernard I., 259-263, *345, *528, *670, *950
Chen, Jeffrey C., 730-731
Cheraskin, E., *593
Chernick, Sidney, 563-570
Chieri, Ramon A., *133, *134
Chiles, Ross, 458-464
Chimenes, H., *345
Chisholm, D. J., *950
Chittenden, Mike, *531
Chlouverakis, C., *670
Chokroverty, Sudhansu, *594
Cholette, Jean-Paul, *349
Chopra, J. S., *529
Chow, Stella Lee, *886
Chowers, I., *469
Churchill, Paul C., *735
Cingolani, Horacio E., *670
Cinotti, Giulio Alberto, *528
Clark, Charles M., Jr., 924-929
Clark, Thomas W., *203
Clarke, B. F., *887
Clemente, Geronima A., *203
Clements, Rex S., Jr., *593
Clinch, J., *133
Cloarec, M., *950-951
Cloutier, Roger J., *594
Cohen, K. L., *593
Cohen, Margo P., *593, 639-643
Cohen, T., 585-590
Cohn, Bruce A., *884
Cole, Harold S., 176-181, *950
Coleman, D. L., *671
Colle, E., *346-347
Collins, John R., *201
Colwell, A. R., Jr., 217-227, 429-437
Conn, Harold O., *671
Conn, Jerome W., 1-10, 102-108, 109-115, *204
Connon, J. J., *529
Conway, Martin J., *738
Cornblath, Marvin, *138
Corredor, D. G., *284, *471, *472, *529
Costin, Gertrude, *347
Cottet, J., *950-951
Cottom, Dennis, *202
Cowley, Ronald, *596
Craw, Linda, *672
Craig, James W., *284-285
Crean, Gerard P., *284
Crespin, Stephen R., *950
Creutzfeldt, W., *347, *593-594, 870-877
Cristol, R., *950-951
Crofford, Oscar B., *201
Crossley, J. N., 450-452
Cryer, Philip E., 519-523
Cuccaro, A. J., *737
Curran, Peter F., *72
Curry, Donald L., 420-428, *528
Curtis-Prior, P. B., *529

D

Dahlqvist, A., *529
Dalferes, Edward R., Jr., 161-170
Damodaran, V. N., *534
Danforth, Elliot, Jr., *344, *472
Daniels, James C., *594
Danowski, T. S., *284, *471, *472, 524-526, *529-530
Daughaday, William H., 519-523
Davidson, Margaret, *884
Davis, J. W., *530
Davis, Walter T., *531-532, *887-888
Daweke, H., *532-533, *598, *673
Dear, H. Davis, *201
Debons, Albert F., *594
Deckert, Torsten, *469-470
De Gasparo, M., *530-531
de Hartog, Maria, *671
De Hertogh, R., *530-531
Delaney, James J., *884
Della Corte, M., 445-449
Del Rio, Alejandro E., *205, *737
de Malbosc, H., *136
Demay, Francois, *349
DeMobray, R. R., *884
Denis, Gustave, *345
DePalma, Ralph G., *202
Deparis, M., *284
Derot, M., *283, *344
Deschamps, I., *671
Deuil, R., *884
Dieterle, C., *133
Dieterle, P., *133
Dhirawani, M. K., *137
Dixit, Padmakar K., *594
Dobson, Harold, *348
Dodge, Billy G., *348
Dolger, Henry, *594-595
Dollery, C. T., 703-714
Done, Alan K., *595
Drake, John W., *595
Driscoll, Shirley G., *470
Dubois, Reuben S., *951
Dugan, Fortune A., 161-170
Dugger, G. S., *591
Dunbar, Joseph C., 603-609
Duprey, J., *670

E

Eaton, R., *530
Eberlein, Walter R., *673
Ecker, Malcolm L., 189-195
Eckhardt, Richard D., *349
Edgar, Paul J., 688-693, *951
Edgren, R. A., *951
Edkins, S. M., *345
Effendic, Suad, *201
Eggenton, J., *591-592
Ehrlich, Robert M., *884-885
Eisentraut, A. M., *200
Elkeles, R. S., *283-284
Elkington, Stephen G., *671
El Masri, A. M., *205
Elsom, Katharine O., *203
Engel, W. K., *134
Englert, Edwin, Jr., 683-687
Ensinck, John W., *409-419
Epstein, Alan N., *533
Erickson, Larry, *201
Ernesti, M., 196-199
Escher, Franz, 502-518
Evans, David A. Price, 234-239, 240-247

F

Fager, Charles A., *671
Fain, John N., *887
Fairney, Angela, *202
Fajans, Stefan S., 1-10, 102-108, 109-115
Fallucca, Francesco, *468-469
Faloona, Gerald R., 614-623, 624-629
Faludi, Georgina, *735
Fang, Victor S., *596
Farquhar, John W., 571-578
Fatourechi, Vahab, *345-346
Fauteux, Jean-Panet, *349
Fedynskyi, Nathalie M., 559-562
Felber, J. P., 81-84, *472

DIABETES: VOLUME 19 (1970) PAGE NUMBERS BY ISSUE

January, 1-80
February, 81-144
March, 145-208
April, 209-288
May, 289-352
Supplement 1, 353-408
June, 409-474
July, 475-538
August, 539-602
September, 603-682
October, 683-746
Supplement 2, 747-830
November, 831-894
December, 895-958

Feldman, Jerome M., 337-343, 475-479, 480-486, *884
Feldman, Marvin J., *470
Felig, Philip, *205-206, 727-729, *885
Felts, James M., *889
Feng, Louise Y., *886
Fenichel, R. L., *951
Ferguson, Arthur W., *885
Ferguson, B. Dan, *345, 438-444, *670
Ferguson, R., *468
Fernandes, J., *202
Field, J. B., *592
Fineberg, S. E., *885, *951
Fischer, Edmond H., *137
Fleischmajer, Raul, *735
Flock, Eunice V., *284
Floquet, A., *346
Floquet, J., *346
Florentin, P., *346
Floyd, John C., Jr., 1-10, 102-108, 109-115
Foa, Piero P., 603-609
Foglia, Virgilio G., *133, *134, *592, *593, 639-643
Forsander, Olof A., *470
Fraser, T. R., *283-284, 703-714, *888
Frasier, S. Douglas, *347
Freeman, Malcolm G., *673
Freeman, Richard M., *888-889
French, F. S., *591
Frerichs, H., *593-594
Frey, Harald M. M., 930-937
Friederici, H. H. R., 33-44
Friedler, Denise, *670
Friedman, L. M., *471, *472
Frohman, Lawrence A., *346
From, Annette, *594
Fujimoto, Wilfred Y., *595
Fulginiti, Vincent A., *951
Furman, Robert H., *595

G

Gale, Charles C., *738
Garcia, L. A., *737
Garcia-Víveros, Mariano, 264-270
Garrison, Mary M., *884
Gastineau, Clifford F., *134
Gatewood, Lael C., 644-655
Gentz, J., *885
Genuth, Saul M., 116-121
Georg, Ralph H., *734-735
George, L. A., *470
Georges, R. J., *887
Geraghty, Michael, *348
Gershberg, Herbert, *134, *470-471
Gershoff, S. N., 296-301
Gharib, Hossein, *134
Ghazal, A. M., *205
Gherondache, Constantin N., *206
Giacometti, Luigi, *671
Gillet, A. P., *468
Gills, James P., Jr., *202
Ginsburg, Jean, 23-27
Glasgow, Allen M., 28-32
Gleason, R. E., *532
Glick, Z., *951
Glitzer, M. S., *737
Goldbloom, R. B., *953
Goldfine, I. D., *735
Goldner, Andrew M., *72
Goldsmith, Stanley J., 453-457
Goldstein, M. S., *735
Goldzieher, J. W., *889
Golob, Erich K., 610-613
Gonzalez-Millan, Heliodoro, *137, 264-270
Goodhead, B., *346-347
Goodman, H. Maurice, *595
Goodman, Stephen I., *284
Goodner, Charles J., *738
Gorden, Phillip, *134
Gordon, Edwin E., *671
Got, O., *137
Gotlin, R. W., *73
Gourevitch, A., *204
Graber, John D., *949
Grande, Francisco, *202
Granitsas, A. N., *672
Grant, A. M., 630-638
Grant, Derek R., *135
Grant, William, *344, *592
Grasso, S., *837-841
Greene, Martin L., *595
Greenen, J. E., *206
Greenough, William B., III, *950
Greider, M. H., *887
Grettie, Donald P., 842-851
Gries, F. A., *951
Griggs, Robert C., *134
Grignon, G., *346
Grimaldi, Richard D., *950
Grodsky, Gerold M., *345, *528, *672, *952
Grossman, Aaron, *530
Gruenewald, D., *735
Grumbach, M. M., *72, *139
Grundahl, Else, *469-470
Grunt, Jerome A., 122-126, *593, *885-886
Guha, Atin, *344
Gulli, R., *349
Gurson, Cihad T., *672
Gutman, R., *952
Gutzeit, A., *889-890
Gwinup, Grant, 11-16

H

Haas, Melvyn, 127-131
Hakkarainen, J., *885
Hales, C. N., *886-887
Hammes, Gordon G., *73
Han, Paul W., *886
Hanley, T., *529
Hansen, Ar. P., *470
Hansen, B. A., *949
Hansen, Robert J., *735-736
Haque, Nasir, *201
Harano, Yutaka, *202
Hardman, J. G., *530
Hardwick, C., 724-726
Harper, A. E., *531
Harrington, Avery R., *73
Hartsuck, James M., *134
Hashim, Sami, A., *953
Havenstein, Nathalie, *736
Haynes, R. C., Jr., *672
Hays, Richard M., *134
Hazzard, William R., *346
Hecht, Arthur, *134
Hegre, Orion D., 906-915
Heilbronner, J., *671
Hellebusch, Arthur A., *470
Hellerström, Claes, *133, *533
Hellman, Bo, *284
Hellman, Dorothea E., *595
Hellstrom, R., *885
Hemraj, B. Chandalia, 863-868
Henderson, Walter J., *206
Henner, J., *133
Herman, Joseph B., 938-943
Hershman, Jerome M., 248-259
Herskovits, Theodore T., *673
Herz, R., *531
Hiatt, Nathan, 307-310
Hildebrand, Hazel E., *597
Hill, J., *596
Himal, H. S., *346-347
Himbert, Jaakko-Juhani, *470
Hitzig, W. H., *953
Hoet, J. J., *530-531
Hohl, R. D., 944-947
Hohler, H., *532
Hollobaugh, Samuel L., 45-49, 50-52
Holtzman, Charles M., *889
Horenstein, M., 70-71
Hornbrook, K. Roger, 916-923
Hoshi, Mitsuru, *347
Hostetler, Karl Y., 554-559
Houareau, M. H., *136
Howard, C. H., *737
Howard, John M., *888
Howell, S. L., *887
Howland, R. J., *951-952
Huijing, F., *202
Hulse, M., *470-471
Hultman, Eric, *344
Hummel, Katharine P., *671
Husband, Peter, *886
Hutton, R. A., *738
Hydovitz, J. D., 524-526
Hyman, Lawrence R., *530

I

Ide, Takehiko, *202
Ingelfinger, Julie R., *134
Ipsen, Johannes, *203

DIABETES: VOLUME 19 (1970) PAGE NUMBERS BY ISSUE

January, 1-80
February, 81-144
March, 145-208
April, 209-288
May, 289-352
Supplement 1, 353-408
June, 409-474
July, 475-538
August, 539-602
September, 603-682
October, 683-746
Supplement 2, 747-830
November, 831-894
December, 895-958

J

Jacobs, Bernard S., 189-195
Jacobson, R., 70-71
Jahnke, K., *532, *673
Jakobson, Theodor, *347
Jaksic, Zelimar, *471
Jan, F., *284
Jarrett, R. J., 724-726
Jeffcoate, S. L., *530
Jewett, Barbara, 50-52
Joffe, B. I., *736
Johansen, Klaus, *470, *597
Johanson, Ann J., *595
Johnson, Allen H., *949
Johnson, B. F., 579-584
Johnson, Irving S., *469
Johnson, Thomas R., *671
Johnstone, Clare G., *139
Jordan, Paul H., *886
Jørgensen, Kai R., *135, *203
Judd, Joseph, 311-323
Jung, August L., *595
Juthani, V. J., *137

K

Kaess, H., *72, *952
Kafka, Marian S., *595-596
Kahanpää, Asko, *347
Kahil, Michel E., *886
Kahn, C. B., *532
Kahn, Harold A., 938-943
Kalbfleisch, John M., 656-663
Kamm, Donald E., *135, *952
Kanazawa, Yasunori, *135-136
Kaneto, Akio, *135
Kaplan, S. L., *72, *139
Kaplan, Solomon A., *347
Kassel, L., 70-71
Kattermann, R., *736, *952
Katz, H. P., *72
Kaufman, Barry J., *135
Kaye, Robert, *201
Kearse, William O., *201-202
Keefe, David M., *531
Keen, H., 724-726
Keiser, G., *469
Keller, P., *736
Kelley, William N., 337-343
Kern, H., 145-154
Khan, A., *596
Khayyal, M. T., *205
Khosla, T., *133
Kiku, Nakao, *135
Kim, Ki-Han, *672
King, Katherine C., *203
King, Lionel R., *596
Kipnis, David M., *73, *530
Kirsteins, L., *596
Knopf, Ralph F., 102-108, 109-115
Knowles, W. R., *348
Köbberling, G., *347
Köbberling, J., *347, *530, *736, 870-877, *952
Kofoed, J. A., 732-733
Kohner, Eva M., 703-714
Koncz, L., *948-949
Konig, Heinrich, 502-518
Kooh, Sang Whay, *884-885
Kosaka, Kinori, *135, *597
Kott, I., 182-185
Kozak, George P., 719-723
Krahl, M. E., *735-736
Kramer, R. M., *948
Krees, S. V., 630-638
Kreisberg, Robert A., 64-69, 248-259
Krimsky, Isidore, *594
Krol, Stefan, *735
Kruger, Fred A., 45-49, 50-52
Krut, L., *736
Kuhns, L. R., *672
Kuo, Peter T., *347-348, *886
Kuperminc, Denis, *949
Kuwabara, Toichiro, *528-529
Kuzuya, Takeshi, *135-136
Kyner, Joseph L., *136

L

Lacy, Paul E., *887, 895-905
Lake, Brian D., *886
Langslow, D. R., *886-887
Lapegue, A., *890
Launay, Marc P., *345
Laurent, J., *346
Lawrence, A. M., *596
Lazarow, Arnold, *594, 906-915
Lazarus, L., *950
Lazarus, N. R., *952
Lazarus, Sydney S., *534
LeBlanc, Raymond P., 715-718
Lebovitz, Harold E., 337-343, 475-479, 480-486, *885
Lech, John J., *670
Lee, John C., *672
Leguillant, F., *284
Lellouche, D., *345
Le Quintrec, Y., *890
Lernmark, Åke, *284
Lestradet, H., *671
Letarte, J., *888
Letteri, Joseph M., *672
Levin, S. R., *952
Levinson, Richard A., 683-687
Lev-Ran, A., 182-185
Lewis, A. A. G., *884
Lewis, George, *202
Lewis, H. Paul, *596
Lewis, Noel, *531
Lewis, W. Frank, *136
Liebermeister, H., *532-533, *598
Lindall, Arnold W., *203-204, *594, *889
Lindholm, Bjorn, *283
Linker, Alfred, *596
Lipschultz, Daniel E., *201-202
Lloyd, Weldon, *596
Lochner, Amanda, *596
Lockwood, Dean H., 688-693
Logothetopoulos, J., 145-154, 539-545
Loken, Susan C., *887
Lombardo, Y. B., *529
London, D. R., *348
Long, W. Newton, *673
Longo, Antonio, *470
Lopez, Nestor L., 271-280, 630-638
Loridan, Liliane, *205, *285, *673
Lo Sardo, G., *532-533, *598
Lotz, Myron, *348
Loubatières, A., *136
Louis, Lawrence H., *204
Loveland, Margaret, *890
Lowrey, G. H., *672
Lowy, C., *283-284
Lozano-Castaneda, Oscar, *137, 264-270
Lu, Y. S., *672
Lubetzki, J., *670
Lucena, Guillermo, *206
Luebben, Gertrude, *138
Luft, Rolf, *201, *469
Lummis, Frederick R., Jr., *285
Luton, J. P., *471

M

Maccario, Micheline, *204
Mace, J. W., *73
Macdonald, I., 450-452
Macfarlane, Dorothy, 842-851, *948
MacLean, L. D., *346-347
MacMillan, Anne, *73
Madsen, Jack A., *596
Mäenpää, Voitto J., *347
Mahler, R. F., *469, *952-953
Maibenco, H. C., 33-44
Mako, Mary, 546-553
Makous, F., *738
Malherbe, C., *530-531
Malins, J. M., 878-880
Malvin, Richard L., *735
Mandelbaum, I., *596-597
Manigand, G., *284
Mann, Jillian R., *204
Mantel, O., *345
Maragoudakis, Michael E., *736
Marble, A., *532
Marco, Jose, 614-623, 624-629
Mariani, M. M., *136
Marks, I. N., *736
Marliss, Errol, 727-729, *885
Marshall, A. M., *887
Marshall, Mary W., *597
Marsters, Robert, 730-731
Martin, D. B., *887

DIABETES: VOLUME 19 (1970) PAGE NUMBERS BY ISSUE

January, 1-80
February, 81-144
March, 145-208
April, 209-288
May, 289-352
Supplement 1, 353-408
June, 409-474
July, 475-538
August, 539-602
September, 603-682
October, 683-746
Supplement 2, 747-830
November, 831-894
December, 895-958

Martin, Helen E., *201, *344, *592
Martin, Julio M., 17-22, *670
Matsubara, T., *531
Matsui, Nobuo, *284, *471
Mayer, J., *951
McDearmon, Marvin, *595
McDonald, Glen W., *136, 852-862
McFadzean, A. J. S., *348
McIlhaney, George R., *886
McKean, Harley, *73
McKiddie, M. T., *597
McLaurin, Robert L., *596
McNay, John L., *887
McNeely, Betty U., *949-950
Medalie, Jack H., 938-943
Meek, Joseph C., *136
Meilman, Edward, *889
Mejia, Jamie A., *285
Melani, Franco, 546-553
Mendelsohn, L. V., *284, *471, *472, *529
Menendez, Celia J., *673
Menzinger, Guido, *468-469
Merimee, T. J., *885, *951
Merrill, Deborah A., *951
Messina, A., *837-841
Messis, Chrystopoulos, *204
Metha, A. B., *137
Metz, Robert, *206, *285
Meyer-Schwickerath, G., *472
Migliorini, R. H., 694-697
Miles, Barbara, *284
Miller, J. E., *468
Miller, Leona V., *201, *344, *592
Miller, Max, *202
Miller, Ralph E., *136, *887
Millward, D. J., *734
Milner, A. D., *348
Milner, R. D. G., *136, *885
Mintz, D. H., *592
Misbin, Robert I., 688-693
Misugi, K., *887
Mitchell, M. L., 196-199
Mizuno, Yoshiatsu, *597
Modigliani, E., *471
Mohos, Steven C., *471
Molnar, George D., *345-346, 644-655
Monteleone, James A., *531
Montes, Leopoldo F., *348
Moody, A. J., *530
Moore, Charles, 610-613
Moore, G., *737
Moorhouse, John A., *135
Morgan, Carl R., *284, *472, *529-530, *594, *596-597
Morgan, E. R., *737
Morrison, Anthony D., *593
Moses, L. E., *889
Moxness, Karen E., *345-346
Munichoodappa, C., 719-723
Munson, Arvid W., *597
Murad, Ferid, *673
Murawski, Benjamin J., 259-263
Murray, Robert L., *951

N

Nabarro, J. D. N., *884
Nadeau, Pierre, *349
Natale, Renato, 228-233
Nechemias, Charles, *594-595
Nelken, L., 585-590
Nelson, Norman C., 302-306
Nestel, Paul J., *736
Neufeld, Henry N., 938-943
Newsome, J. F., *591
Nielsen, J. H., *949
Nielsen, Johannes, *597
Nijjar, M. S., 155-160
Niki, A., *137-138
Niki, H., *137-138
Nissley, Simon P., *134
Nordöy, Arne, 698-702
Norum, Robert A., *949
Novak, Milan, 563-570
Nowell, N. W., *951-952
Nyhan, William L., *735

O

Oakley, N. W., *884
Oberdisse, K., *951
O'Brien, Donough, *284, 831-836
O'Brien, John J., *471-472
O'Hara, David, *598
Ohgawara, Hisako, *597
Ohman, John L., 727-729
Ohrenberg, Cynthia, *139
Oldershausen, H.-F.v., *531
Olsen, W. A., *736-737
Ondetti, Miguel A., *737
Oran, Erdogan, *887
Ostrander, Leon D., *597-598
O'Sullivan, J. B., *136-137
Owen, Charles A., *284

P

Padron, Jorge L., *531
Pairent, Frederick W., *888
Pak, Charles Y. C., *595-596
Pallotta, Johanna A., 122-126
Palmer, Darwin L., 881-883
Pamintaun, Jose, *886
Park, Heebock, *73
Park, Sungmin, *735
Parker, D. C., *73
Parra, Adalberto, *204, 492-501
Patel, J. C., *137
Patrick, A. D., *886
Paul, Oglesby, *73
Paul, Pavle, *204
Pearce, N., *469
Pearson, A. W., *886-887
Pearson, Howard A., *533-534
Pek, Sumer, 102-108, 109-115
Peng, Y., *531
Pennington, Lloyd F., 64-69, 248-249
Penny, Robert, *531-532, *887-888
Perlstein, Tamar, 938-943
Perry, W. F., 155-160
Persson, Bengt, *885, *953
Phillips, Leo I., *592
Pidduck, Heather G., 234-239, 240-247
Pierce, Lawrence E., *471-472
Pilkis, Simon J., *735-736
Pincus, Gregory, *206
Piras, Romano, *137
Pi-Sunyer, F. Xavier, *348, *953
Pitkin, Roy M., 85-90, *888
Plager, John E., *284, *471
Plevin, S. N., *953
Plusec, Josip, *737
Podolsky, Stephen, 438-444
Pollack, Shlomo, *284
Porte, Daniel, Jr., *592, *598
Poucher, Russell L., 11-16
Pozefsky, T., *885
Prasad, M., *953
Prenton, M. A., *348
Price, Thomas, *598
Prueh, E. D. R., *888
Ptacek, John, *884
Purse, R. M., *951
Pyke, D. A., 878-880

Q

Quibrera, Ricardo, *137, 264-270

R

Raben, M. S., 196-199
Rabinowitz, D., *951
Radhakrishnamurthy, Bhandaru, 161-170, 176-181
Ralph, C., *201
Ramachandran, S., *204-205
Ramirez, Rafael, *596
Rao, M. Bhaskar, 45-49
Rasio, E. A., *472
Rastogi, G. K., *888
Rastogi, Krishna Sudha, *593
Rathgeb, Isabel, 487-491
Rauber, G., *346
Rayner, P. H. W., *204
Reaven, Gerald M., 571-578
Recant, L., *952
Reefe, William E., *470
Rees, Richard B., 11-16
Rees, Searle, *345
Reid, Leroy R., 209-216
Reid, R. A., *953
Rennert, Owen M., *888
Renold, A. E., *345
Reusch, C. S., *532
Reynolds, David W., *885-886

DIABETES: VOLUME 19 (1970) PAGE NUMBERS BY ISSUE

January, 1-80
February, 81-144
March, 145-208
April, 209-288
May, 289-352
Supplement 1, 353-408
June, 409-474
July, 475-538
August, 539-602
September, 603-682
October, 683-746
Supplement 2, 747-830
November, 831-894
December, 895-958

Reynolds, Ernest W., *738
Reynolds, W. Ann, 85-90, *888
Ribeirao, Preto, 694-697
Ribes, G., *136
Rigopoulou, Demetra, 614-623, 624-629
Rimoin, David L., *532
Ringsdorf, W. J. M., Jr., *593
Riss, Egon, 938-943
Rishi, Surendra, 610-613
Ritchie, D., *204-205
Robbins, T. J., *529-530
Roberts, Norbert J., *203
Roch-Norlund, Aasmund E., *344
Rödset, J. M., 698-702
Rogers, Jerry B., *888
Rogus, Ellen, *598
Rojas, L., *532
Romani, J. D., *137
Romano, S., 445-449
Root, Allen W., *673
Root, Mary A., *469
Rosenberg, I. H., *736-737
Rosenfeld, Paul S., *472
Rosenlund, Bent, 930-937
Rosenlund, Mary Loretta, *284
Rosevear, John W., *345, 644-655
Rossman, L. G., *73
Roth, Jesse, *134
Roux, Jacques F., *534
Roy, Claude C., *951
Rubenstein, Arthur H., *472, 546-553, *737
Rudman, Daniel, *205, *737
Ruiz, Harold, 161-170
Rull, Juan A., 1-10, *137, 264-270
Ruschhaupt, David G., *888
Rutstein, D. D., *670
Ryan, Jerome R., 259-263
Rzeszotarski, W. J., 579-584

S

Sabeh, G., *284, *471, *472, *529-530
Sabo, Emily F., *737
Sachsse, B., *673
Sachsse, R., *673
Saleh, Samira, *205
Samaan, Naguib A., *284-285, *349, *888-889
Samuel, Paul, *889
Saner, Gunay, *672
Saporito, N., *837-841
Sarcione, E. J., *349
Sarin, Raj K., 11-16
Saroff, Jack, 311-323
Sassin, J. F., *73
Saunders, R. A., *468
Sawayama, Toshitami, *201
Schimpff, Stephen C., *205-206
Schlierf, G., *72, *952
Schmidt, Felix H., *533
Schmitt, H., *532-533, *598
Schnatz, J. David, *346
Schonbaum, Eduard, *890
Schreiber, William, *671
Schultz, Robert B., *204, 492-501
Schultz, Stanley G., *72
Schwartz, P. L., 465-466
Schwartz, Robert, *203
Schwarz, K., *133
Scott, James P., 842-851
Scow, Robert O., 924-929
Scriver, Charles R., *205
Scullard, G. H., *734
Searle, G. L., *349
Seegmiller, J. Edwin, *595
Sekowski, Ignacy, *889
Senior, Boris, *205, *285, *595, *673
Serio, M., 445-449
Service, Frederick J., *345-346, 644-655
Sevilla, Cynthia L., *137
Shah, Narendra, 610-613
Shahani, B., *472
Shani Mishkinsky, J., *468
Shapcott, Dennis, 831-836
Shaw, Walter N., 209-216
Sheehan, John T., *737
Sheffer, Albert L., *139
Shenkman, Louis, 127-131
Shreeve, Walton W., *347
Sidransky, H., *533
Sieracki, J. C., *284, *471, *529-530
Silvers, Abraham, 571-578
Simmonds, Anne, *592
Simpson, John C. F., 881-883
Sirek, A., *137-138
Sirek, O. V., *137-138
Sisk, Charles W., 852-862
Skillman, Thomas G., *737-738
Skoza, Lorant, *471
Skrabalo, Zdenko, *471
Smith, D. F., *952
Smith, George F., *735
Smith, Gerard P., *533
Smyth, D. H., *591-592
Snodgrass, Graeme J. A. I., *72, *886
Sodoyez, Jean-Claude, 603-609
Sodoyez-Goffaux, Francoise, 603-609
Soeldner, J. Stuart, 122-126, *136, *139, *532, *534
Soergel, K. H., *206
Sokal, J. E., *349
Sorenson, G. D., *887
Sorenson, Robert L., *203-204, *889
Souchal, B., *283, *344
Spalding, J. M. K., *472
Spellacy, C. E., *889
Spellacy, William N., *598, *735, *889
Spencer, M. L., *672
Spenney, Jerry G., 248-259
Spiger, Michael J., *346
Spiro, R. G., *949
Spitz, I. M., *737
Srinivasan, S. R., 171-175
Staba, Margaret A., *889
Stacpoole, Peter W., *889
Staneloni, Roberto, *137
Stauffacher, W., *345, *889-890
Stauffer, U. G., *953
Steele, Ann A., 91-97, *592-593
Steele, Robert, 487-491
Steelman, S. L., *737
Steffes, Michael W., *203, *889
Steinberg, Daniel, *950
Steinberg, Terry, 11-16
Steiner, Donald F., 546-553
Steiner, George, *890
Steinke, Jurgen, *202, *470
Stenhouse, N. S., *139
Stewart, G. A., *529
Stewart, John, 852-862
Stirati, Giovanni, *528
Stoll, Ralph W., 409-419
Stone, Daniel B., 91-97, *349, *592-593
Stoppani, A. O. M., *592
Stork, Harald, *533
Stout, R. W., *138, *205
Strauch, Barry S., *205-206
Strauch, G., *471
Sulman, F. G., *468
Sunder, J. H., *284, *472, *529-530
Sunderman, Carolyn R., *533-534
Surmaczynska, Barbara, *206, *285
Sussman, Karl E., *734-735
Sutherland, E. W., *530
Sutton, P. M., *285, *349
Svenningsen, N. W., *529
Swann, John C., *73
Swiatek, Kenneth R., *138
Szabo, Olga, *952-953

T

Taghizadeh, A., *285, *349
Taljedal, I. B., *534
Tamburrano, Guido, *468-469
Tanese, T., *952
Tasaka, Yoshimasa, *135, *597
Tashjian, Armen, *596
Taylor, Alfred M., *73
Taylor, Enid, *948
Taylor, William F., *345-346, 644-655
Tchobroutsky, G., *283, *344
Teuscher, Arthur, 502-518
Theodoridis, C. G., *138, *890
Thiffault, Charles A., 102-108, 109-115
Thomas, M., *890
Thomsen, J., *344
Thorell, Jan I., *737, *953
Timmons, R. L., *591
Tobin, Jordan D., *534
Tochino, Y., *531
Toomey, Richard E., 209-216
Touber, Jan L., 409-419
Touborg, Jens N. F., *670
Troedel, M. A., 465-466
Trethewey, J., *529
Tsai, C. T., *529-530
Turnbull, A. C., *133
Tyce, Gertrude M., *284
Tzagournis, Manuel, 458-464, *737-738

DIABETES: VOLUME 19 (1970) PAGE NUMBERS BY ISSUE

January, 1-80
February, 81-144
March, 145-208
April, 209-288
May, 289-352
Supplement 1, 353-408
June, 409-474
July, 475-538
August, 539-602
September, 603-682
October, 683-746
Supplement 2, 747-830
November, 831-894
December, 895-958

U

Unger, Roger H., *200, 614-623, 624-629
Updike, Stuart J., *73
Urca, I., 182-185

V

Vaishnava, H., *534
Vallance-Owen, J., *138, *670
Vallet, H. L., *953
Valverde, Isabel, 614-623, 624-629
Vance, James E., *598
Van De Kamer, J. H., *202
Vander Ark, Condon R., *738
Van Itallie, Theodore B., *348
Van Orden, Dianna E., *888
Van Wyk, J. J., *591
Varady, John C., 664-669
Varandani, P. T., 98-101
Vargas, L., 33-44
Varnauskas, Edvardas, *283
Vaughan, Martha, *673
Vela, A. Richard, *738
Verdy, Maurice, *349
Verney, E., *533
Vester, J. W., *471
Vigas, M., *137-138
Viktora, Josef, 271-280
Viskum, K., *138
Voeghelin, M. R., 445-449
Volk, Bruno W., *534
Von Mikulicz-Radecki, J. G., *952
Vracko, Rudolf, *890
Vranic, M., *138

W

Waddell, Carolin C., *138
Wagle, D. S., *532
Wagle, S. R., *204-205
Waitzkin, Leo, 186-188
Waldhäusl, W., *534
Walfish, Paul G., 228-233
Walker, W., *737
Warner, Richard A., *138-139
Weaver, R. P., *591
Weich, N. L., 296-301
Weinstein, Jacob J., *344
Weintraub, R., *349
Weissman, Peter, 127-131
Weitzner, Stanley, 881-883
Welborn, T. A., *139
Welbourne, W. Porter, 546-553
Wellmann, Klaus F., *534
Wells, Herbert, *596
Wells, Lemen J., 906-915
Werrbach, Jon H., *738
Wessing, A., *472
Wesson, Laurence G., *672
West, Kelly M., 656-663
Westman, Sighild, *133, *533
Wettenhall, R. E. H., 465-466
Wexler, Bernard C., 311-323, 324-336
Whalen, G. E., *206
Wheeler, Clayton E., *884
Whitby, L. G., *887
Whitcomb, Frederick F., Jr., *285
White, P. A., *670
Widström, A., *469
Wieland, Ralph G., 730-731
Williams, Gerald A., *206
Williams, Hollis R., 554-559
Williams, J. W., *890
Williams, Nina, *737
Williams, Robert H., *409-419, *598
Wilson, Robert B., 17-22
Winegrad, Albert I., *593
Wingert, J. P., *284, 524-526
Winkler, Bertram, 487-491
Wolff, Frederick W., 271-280, 630-638
Wolfsohn, H., 585-590
Wolfson, Sorrell L., *735
Womack, Madelyn, *597
Wong, Paul W., *530
Woods, S. C., *738
Wool, Marvin S., *472
Wren, Peter J. J., 234-239, 240-247
Wrenshall, G. A., *138
Wright, A. D., *283-284
Wrigley, Wayne, *201

Y

Yalow, Rosalyn S., 453-457
Yde, Hans, *597
Yeung, R. T. T., *348
Yip, C. C., 539-545
Yodaiken, Ralph E., 664-669
Youlton, R., *72, *139
Young, J. D., *950
Young, Wilma K., 209-216
Younger, Donna, *345
Yu, Pao-lo, 289-295
Yu, Yaw-Kaung, *886

Z

Zuckerman, Leon, 217-227, 429-437

DIABETES: VOLUME 19 (1970) PAGE NUMBERS BY ISSUE

January, 1-80
February, 81-144
March, 145-208
April, 209-288
May, 289-352
Supplement 1, 353-408
June, 409-474
July, 475-538
August, 539-602
September, 603-682
October, 683-746
Supplement 2, 747-830
November, 831-894
December, 895-958